{ "disease": "bladder-cancer", "label": "Bladder cancer", "url": "https://usebiotransfer.org/disease/bladder-cancer/", "built": "2026-09-12", "facts_hash": { "answers": "3cbc357eddb3", "targets": "1b8fde2cc8f6" }, "sources": { "targets": "Open Targets Platform GraphQL API v4", "trials": "ClinicalTrials.gov API v2" }, "retrieved": { "targets": "2026-09-12", "trials": "2026-09-12" }, "query": { "endpoint": "https://clinicaltrials.gov/api/v2/studies", "shape": "query.cond=&query.intr=&pageSize=200", "active_statuses": [ "ACTIVE_NOT_RECRUITING", "ENROLLING_BY_INVITATION", "NOT_YET_RECRUITING", "RECRUITING" ], "dedup": "by NCT id across synonyms", "study_types": "interventional counted in headline; observational reported separately", "known_floor": "trials naming an antigen only by product code are not retrieved by an intervention-name search" }, "targets": [ { "symbol": "FGFR3", "ensembl": "ENSG00000068078", "n_drug_entries": 25, "n_distinct_drugs": 23, "drugs": { "BRIVANIB": "PHASE_3", "BRIVANIB ALANINATE": "PHASE_3", "DERAZANTINIB": "PHASE_3", "DOVITINIB": "PHASE_3", "E-7090": "APPROVAL", "ENMD-2076": "PHASE_2", "ENMD-981693": "PHASE_2", "ERDAFITINIB": "APPROVAL", "FEXAGRATINIB": "PHASE_2", "FGFR INHIBITOR DEBIO 1347": "PHASE_2", "FUTIBATINIB": "APPROVAL", "HMPL-453": "PHASE_2", "INFIGRATINIB": "APPROVAL", "LY-2874455": "PHASE_2", "MASITINIB": "APPROVAL", "NINTEDANIB": "APPROVAL", "NINTEDANIB ESYLATE": "APPROVAL", "ORANTINIB": "PHASE_3", "PAZOPANIB": "APPROVAL", "PEMIGATINIB": "APPROVAL", "ROGARATINIB": "PHASE_2_3", "VOFATAMAB": "PHASE_2", "XL-999": "PHASE_2" }, "approved": [ "E-7090", "ERDAFITINIB", "FUTIBATINIB", "INFIGRATINIB", "MASITINIB", "NINTEDANIB", "NINTEDANIB ESYLATE", "PAZOPANIB", "PEMIGATINIB" ], "n_approved": 9, "approved_for": { "E-7090": [ "biliary tract cancer" ], "ERDAFITINIB": [ "urothelial carcinoma", "urinary bladder carcinoma" ], "FUTIBATINIB": [ "biliary tract cancer", "intrahepatic cholangiocarcinoma", "cholangiocarcinoma" ], "INFIGRATINIB": [ "cholangiocarcinoma" ], "MASITINIB": [], "NINTEDANIB": [ "idiopathic pulmonary fibrosis", "colorectal cancer", "interstitial lung disease", "systemic sclerosis", "pulmonary fibrosis" ], "NINTEDANIB ESYLATE": [ "idiopathic pulmonary fibrosis", "systemic sclerosis", "non-small cell lung carcinoma", "Interstitial pneumonitis" ], "PAZOPANIB": [ "renal cell carcinoma", "soft tissue sarcoma", "sarcoma" ], "PEMIGATINIB": [ "biliary tract cancer", "cholangiocarcinoma" ] }, "tractability": [ { "modality": "SM", "bucket": "Approved Drug" }, { "modality": "SM", "bucket": "Structure with Ligand" }, { "modality": "SM", "bucket": "High-Quality Ligand" }, { "modality": "SM", "bucket": "Druggable Family" }, { "modality": "AB", "bucket": "Phase 1 Clinical" }, { "modality": "AB", "bucket": "GO CC high conf" }, { "modality": "AB", "bucket": "UniProt loc med conf" }, { "modality": "AB", "bucket": "UniProt SigP or TMHMM" }, { "modality": "PR", "bucket": "UniProt Ubiquitination" }, { "modality": "PR", "bucket": "Database Ubiquitination" }, { "modality": "PR", "bucket": "Small Molecule Binder" }, { "modality": "OC", "bucket": "Advanced Clinical" } ] }, { "symbol": "ERBB2", "ensembl": "ENSG00000141736", "n_drug_entries": 48, "n_distinct_drugs": 45, "drugs": { "AC-480": "PHASE_2", "AEE-788": "PHASE_1_2", "AFATINIB": "APPROVAL", "AFATINIB DIMALEATE": "APPROVAL", "ALLITINIB": "PHASE_1", "ANVATABART OPADOTIN": "PHASE_2_3", "AV-412": "PHASE_1", "BMS-690514": "PHASE_2", "CANERTINIB": "PHASE_2", "CP-724714": "PHASE_2", "CUDC-101": "PHASE_1", "DACOMITINIB": "APPROVAL", "DISITAMAB VEDOTIN": "PHASE_3", "ERTUMAXOMAB": "PHASE_2", "GANCOTAMAB": "PHASE_2_3", "HEMAY-022": "PHASE_3", "JNJ-26483327": "PHASE_1", "KBP5209": "PHASE_1", "KN-026": "PHASE_3", "LAPATINIB": "APPROVAL", "LAPATINIB DITOSYLATE": "APPROVAL", "MARGETUXIMAB": "APPROVAL", "MASOPROCOL": "APPROVAL", "MM-111": "PHASE_2", "MUBRITINIB": "PHASE_1", "NERATINIB": "APPROVAL", "PERTUZUMAB": "APPROVAL", "POZIOTINIB": "PHASE_3", "PYROTINIB": "PHASE_3", "S-222611": "PHASE_1", "SAPITINIB": "PHASE_2", "TAK-285": "PHASE_1", "TARLOXOTINIB": "PHASE_2", "TESEVATINIB": "PHASE_3", "TRASTUZUMAB": "APPROVAL", "TRASTUZUMAB BOTIDOTIN": "PHASE_3", "TRASTUZUMAB DERUXTECAN": "APPROVAL", "TRASTUZUMAB DUOCARMAZINE": "APPROVAL", "TRASTUZUMAB EMTANSINE": "APPROVAL", "TUCATINIB": "APPROVAL", "TUXOBERTINIB": "PHASE_1_2", "VANDETANIB": "APPROVAL", "VARLITINIB": "PHASE_2_3", "ZANIDATAMAB": "APPROVAL", "ZENOCUTUZUMAB": "APPROVAL" }, "approved": [ "AFATINIB", "AFATINIB DIMALEATE", "DACOMITINIB", "LAPATINIB", "LAPATINIB DITOSYLATE", "MARGETUXIMAB", "MASOPROCOL", "NERATINIB", "PERTUZUMAB", "TRASTUZUMAB", "TRASTUZUMAB DERUXTECAN", "TRASTUZUMAB DUOCARMAZINE", "TRASTUZUMAB EMTANSINE", "TUCATINIB", "VANDETANIB", "ZANIDATAMAB", "ZENOCUTUZUMAB" ], "n_approved": 17, "approved_for": { "AFATINIB": [ "non-small cell lung carcinoma" ], "AFATINIB DIMALEATE": [ "non-small cell lung carcinoma" ], "DACOMITINIB": [ "non-small cell lung carcinoma" ], "LAPATINIB": [ "breast cancer" ], "LAPATINIB DITOSYLATE": [ "breast cancer", "breast neoplasm", "breast carcinoma" ], "MARGETUXIMAB": [ "HER2 positive breast carcinoma", "breast cancer" ], "MASOPROCOL": [ "prostate cancer" ], "NERATINIB": [ "breast cancer", "breast neoplasm", "breast carcinoma" ], "PERTUZUMAB": [ "breast cancer", "breast carcinoma", "breast neoplasm" ], "TRASTUZUMAB": [ "breast cancer", "breast carcinoma", "gastric cancer", "gastric neoplasm", "breast neoplasm" ], "TRASTUZUMAB DERUXTECAN": [ "breast cancer", "HER2 positive breast carcinoma", "breast neoplasm" ], "TRASTUZUMAB DUOCARMAZINE": [], "TRASTUZUMAB EMTANSINE": [ "breast cancer", "breast carcinoma", "breast neoplasm" ], "TUCATINIB": [ "HER2 positive breast carcinoma", "metastasis", "breast neoplasm", "breast cancer", "colorectal carcinoma", "breast carcinoma" ], "VANDETANIB": [ "thyroid gland carcinoma", "medullary thyroid gland carcinoma", "thyroid tumor" ], "ZANIDATAMAB": [ "biliary tract neoplasm" ], "ZENOCUTUZUMAB": [ "non-small cell lung carcinoma", "pancreatic neoplasm" ] }, "tractability": [ { "modality": "SM", "bucket": "Approved Drug" }, { "modality": "SM", "bucket": "Structure with Ligand" }, { "modality": "SM", "bucket": "High-Quality Ligand" }, { "modality": "SM", "bucket": "High-Quality Pocket" }, { "modality": "SM", "bucket": "Druggable Family" }, { "modality": "AB", "bucket": "Approved Drug" }, { "modality": "AB", "bucket": "UniProt loc high conf" }, { "modality": "AB", "bucket": "GO CC high conf" }, { "modality": "AB", "bucket": "UniProt SigP or TMHMM" }, { "modality": "AB", "bucket": "Human Protein Atlas loc" }, { "modality": "PR", "bucket": "Literature" }, { "modality": "PR", "bucket": "Database Ubiquitination" }, { "modality": "PR", "bucket": "Half-life Data" }, { "modality": "PR", "bucket": "Small Molecule Binder" }, { "modality": "OC", "bucket": "Approved Drug" } ] }, { "symbol": "NECTIN4", "ensembl": "ENSG00000143217", "n_drug_entries": 1, "n_distinct_drugs": 1, "drugs": { "ENFORTUMAB VEDOTIN": "APPROVAL" }, "approved": [ "ENFORTUMAB VEDOTIN" ], "n_approved": 1, "approved_for": { "ENFORTUMAB VEDOTIN": [ "urothelial carcinoma", "transitional cell carcinoma" ] }, "tractability": [ { "modality": "AB", "bucket": "UniProt loc high conf" }, { "modality": "AB", "bucket": "GO CC high conf" }, { "modality": "AB", "bucket": "UniProt SigP or TMHMM" }, { "modality": "AB", "bucket": "Human Protein Atlas loc" }, { "modality": "OC", "bucket": "Approved Drug" } ] }, { "symbol": "TACSTD2", "ensembl": "ENSG00000184292", "n_drug_entries": 2, "n_distinct_drugs": 2, "drugs": { "DATOPOTAMAB DERUXTECAN": "APPROVAL", "SACITUZUMAB GOVITECAN": "APPROVAL" }, "approved": [ "DATOPOTAMAB DERUXTECAN", "SACITUZUMAB GOVITECAN" ], "n_approved": 2, "approved_for": { "DATOPOTAMAB DERUXTECAN": [ "breast cancer", "breast neoplasm", "non-small cell lung carcinoma" ], "SACITUZUMAB GOVITECAN": [ "breast cancer", "urothelial carcinoma", "triple-negative breast carcinoma", "breast neoplasm" ] }, "tractability": [ { "modality": "AB", "bucket": "UniProt SigP or TMHMM" }, { "modality": "AB", "bucket": "GO CC med conf" }, { "modality": "AB", "bucket": "Human Protein Atlas loc" }, { "modality": "PR", "bucket": "Database Ubiquitination" }, { "modality": "OC", "bucket": "Approved Drug" } ] }, { "symbol": "CD274", "ensembl": "ENSG00000120217", "n_drug_entries": 13, "n_distinct_drugs": 13, "drugs": { "ADEBRELIMAB": "PHASE_3", "ATEZOLIZUMAB": "APPROVAL", "AVELUMAB": "APPROVAL", "BINTRAFUSP ALFA": "PHASE_3", "COSIBELIMAB": "APPROVAL", "DANBURSTOTUG": "PHASE_2", "DURVALUMAB": "APPROVAL", "ENVAFOLIMAB": "PHASE_3", "ERFONRILIMAB": "PHASE_3", "INCB-086550": "PHASE_2", "PACMILIMAB": "PHASE_2", "SOCAZOLIMAB": "PHASE_3", "SUGEMALIMAB": "APPROVAL" }, "approved": [ "ATEZOLIZUMAB", "AVELUMAB", "COSIBELIMAB", "DURVALUMAB", "SUGEMALIMAB" ], "n_approved": 5, "approved_for": { "ATEZOLIZUMAB": [ "urothelial carcinoma", "non-small cell lung carcinoma", "breast cancer", "small cell lung carcinoma", "breast neoplasm", "transitional cell carcinoma" ], "AVELUMAB": [ "Merkel cell skin cancer", "urothelial carcinoma", "neuroendocrine neoplasm" ], "COSIBELIMAB": [ "head and neck squamous cell carcinoma" ], "DURVALUMAB": [ "non-small cell lung carcinoma", "small cell lung carcinoma", "urothelial carcinoma", "hepatocellular carcinoma" ], "SUGEMALIMAB": [ "non-small cell lung carcinoma" ] }, "tractability": [ { "modality": "SM", "bucket": "Structure with Ligand" }, { "modality": "SM", "bucket": "High-Quality Ligand" }, { "modality": "SM", "bucket": "Med-Quality Pocket" }, { "modality": "AB", "bucket": "Approved Drug" }, { "modality": "AB", "bucket": "UniProt loc high conf" }, { "modality": "AB", "bucket": "GO CC high conf" }, { "modality": "AB", "bucket": "UniProt SigP or TMHMM" }, { "modality": "PR", "bucket": "Literature" }, { "modality": "PR", "bucket": "UniProt Ubiquitination" }, { "modality": "PR", "bucket": "Small Molecule Binder" }, { "modality": "OC", "bucket": "Advanced Clinical" } ] }, { "symbol": "TP53", "ensembl": "ENSG00000141510", "n_drug_entries": 9, "n_distinct_drugs": 8, "drugs": { "ALRIZOMADLIN": "PHASE_2", "CENERSEN": "PHASE_2", "CONTUSUGENE LADENOVEC": "PHASE_3", "EPRENETAPOPT": "PHASE_3", "IDASANUTLIN": "PHASE_3", "NAVTEMADLIN": "PHASE_3", "SIREMADLIN": "PHASE_2", "TEPRASIRAN": "PHASE_3" }, "approved": [], "n_approved": 0, "approved_for": {}, "tractability": [ { "modality": "SM", "bucket": "Advanced Clinical" }, { "modality": "SM", "bucket": "Structure with Ligand" }, { "modality": "SM", "bucket": "High-Quality Ligand" }, { "modality": "SM", "bucket": "Med-Quality Pocket" }, { "modality": "SM", "bucket": "Druggable Family" }, { "modality": "PR", "bucket": "UniProt Ubiquitination" }, { "modality": "PR", "bucket": "Database Ubiquitination" }, { "modality": "PR", "bucket": "Small Molecule Binder" }, { "modality": "OC", "bucket": "Advanced Clinical" } ] }, { "symbol": "RB1", "ensembl": "ENSG00000139687", "n_drug_entries": 0, "n_distinct_drugs": 0, "drugs": {}, "approved": [], "n_approved": 0, "approved_for": {}, "tractability": [ { "modality": "SM", "bucket": "High-Quality Ligand" }, { "modality": "SM", "bucket": "Med-Quality Pocket" }, { "modality": "SM", "bucket": "Druggable Family" }, { "modality": "PR", "bucket": "Database Ubiquitination" }, { "modality": "PR", "bucket": "Half-life Data" }, { "modality": "PR", "bucket": "Small Molecule Binder" } ] }, { "symbol": "KDM6A", "ensembl": "ENSG00000147050", "n_drug_entries": 0, "n_distinct_drugs": 0, "drugs": {}, "approved": [], "n_approved": 0, "approved_for": {}, "tractability": [ { "modality": "SM", "bucket": "Structure with Ligand" }, { "modality": "SM", "bucket": "High-Quality Ligand" }, { "modality": "SM", "bucket": "Med-Quality Pocket" }, { "modality": "PR", "bucket": "Database Ubiquitination" }, { "modality": "PR", "bucket": "Half-life Data" }, { "modality": "PR", "bucket": "Small Molecule Binder" } ] }, { "symbol": "ARID1A", "ensembl": "ENSG00000117713", "n_drug_entries": 0, "n_distinct_drugs": 0, "drugs": {}, "approved": [], "n_approved": 0, "approved_for": {}, "tractability": [ { "modality": "PR", "bucket": "Database Ubiquitination" }, { "modality": "PR", "bucket": "Half-life Data" } ] }, { "symbol": "PIK3CA", "ensembl": "ENSG00000121879", "n_drug_entries": 32, "n_distinct_drugs": 31, "drugs": { "ALPELISIB": "APPROVAL", "APITOLISIB": "PHASE_2", "AZD-6482": "UNKNOWN", "BAY-1082439": "PHASE_1", "BGT-226": "PHASE_1_2", "BUPARLISIB": "PHASE_3", "COPANLISIB": "APPROVAL", "DACTOLISIB": "PHASE_3", "DS-7423": "PHASE_1", "FIMEPINOSTAT": "PHASE_2", "GEDATOLISIB": "PHASE_3", "GSK-1059615": "PHASE_1", "INAVOLISIB": "APPROVAL", "IZORLISIB": "PHASE_1_2", "OMIPALISIB": "PHASE_1", "PANULISIB": "PHASE_1", "PAXALISIB": "PHASE_2_3", "PF-04691502": "PHASE_2", "PICTILISIB": "PHASE_2", "PILARALISIB": "PHASE_2", "PKI-179": "PHASE_1", "RECILISIB": "PHASE_1", "SAMOTOLISIB": "PHASE_2", "SERABELISIB": "PHASE_2", "SF-1126": "PHASE_2", "SONOLISIB": "PHASE_2", "TASELISIB": "PHASE_3", "VOXTALISIB": "PHASE_2", "VS-5584": "PHASE_1", "WX-037": "PHASE_1", "ZSTK-474": "PHASE_1" }, "approved": [ "ALPELISIB", "COPANLISIB", "INAVOLISIB" ], "n_approved": 3, "approved_for": { "ALPELISIB": [ "breast cancer", "breast neoplasm", "breast carcinoma" ], "COPANLISIB": [ "follicular lymphoma", "non-Hodgkin lymphoma", "neoplasm of mature B-cells" ], "INAVOLISIB": [ "breast neoplasm" ] }, "tractability": [ { "modality": "SM", "bucket": "Approved Drug" }, { "modality": "SM", "bucket": "Structure with Ligand" }, { "modality": "SM", "bucket": "High-Quality Ligand" }, { "modality": "SM", "bucket": "High-Quality Pocket" }, { "modality": "SM", "bucket": "Druggable Family" }, { "modality": "AB", "bucket": "GO CC med conf" }, { "modality": "PR", "bucket": "Literature" }, { "modality": "PR", "bucket": "Database Ubiquitination" }, { "modality": "PR", "bucket": "Half-life Data" }, { "modality": "PR", "bucket": "Small Molecule Binder" } ] }, { "symbol": "TERT", "ensembl": "ENSG00000164362", "n_drug_entries": 2, "n_distinct_drugs": 1, "drugs": { "IMETELSTAT": "APPROVAL" }, "approved": [ "IMETELSTAT" ], "n_approved": 1, "approved_for": { "IMETELSTAT": [ "anemia", "myelodysplastic syndrome" ] }, "tractability": [ { "modality": "SM", "bucket": "High-Quality Ligand" }, { "modality": "SM", "bucket": "Druggable Family" }, { "modality": "AB", "bucket": "GO CC med conf" }, { "modality": "PR", "bucket": "UniProt Ubiquitination" }, { "modality": "PR", "bucket": "Small Molecule Binder" }, { "modality": "OC", "bucket": "Advanced Clinical" } ] }, { "symbol": "STAG2", "ensembl": "ENSG00000101972", "n_drug_entries": 0, "n_distinct_drugs": 0, "drugs": {}, "approved": [], "n_approved": 0, "approved_for": {}, "tractability": [ { "modality": "PR", "bucket": "Database Ubiquitination" }, { "modality": "PR", "bucket": "Half-life Data" } ] } ], "trials": { "by_antigen": { "Nectin-4": { "n": 52, "n_observational": 3, "n_active": 45, "n_withdrawn": 0, "trials": [ { "nct": "NCT04724018", "title": "Sacituzumab Govitecan Plus EV in Metastatic UC", "status": "RECRUITING", "last_update": "2025-11-04", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04878029", "title": "Cabozantinib in Combination With Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial Cancer", "status": "RECRUITING", "last_update": "2026-04-29", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05126472", "title": "Study of 2141-V11 in People With Non-muscle Invasive Bladder Cancer That Did Not Respond to Standard Treatment", "status": "RECRUITING", "last_update": "2026-08-14", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05239624", "title": "Enfortumab Vedotin and Pembrolizumab in People With Bladder Cancer", "status": "RECRUITING", "last_update": "2026-06-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05614739", "title": "FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3", "status": "RECRUITING", "last_update": "2026-08-20", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05656235", "title": "Renal Retention in High Grade Upper Tract Urothelial Cancer", "status": "RECRUITING", "last_update": "2026-01-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05756569", "title": "Enfortumab Vedotin Plus Pembrolizumab for the Treatment of Locally Advanced or Metastatic Bladder Cancer of Variant Histology", "status": "RECRUITING", "last_update": "2026-07-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05879653", "title": "Pembrolizumab and EV With Radiation Therapy for MIBC Patients (PEVRAD)", "status": "RECRUITING", "last_update": "2025-08-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06041503", "title": "Enfortumab Vedotin With or Without Pembrolizumab in Rare Genitourinary Tumors (E-VIRTUE)", "status": "RECRUITING", "last_update": "2026-08-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06394570", "title": "Enfortumab Vedotin and Stereotactic Radiation for Localized, Cisplatin Ineligible Muscle Invasive Bladder Cancer", "status": "RECRUITING", "last_update": "2025-09-15", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06434350", "title": "Enfortumab Vedotin With Radiation for Locally Advanced Bladder Cancer (CONSOLIDATE)", "status": "RECRUITING", "last_update": "2026-06-15", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06465069", "title": "A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors", "status": "RECRUITING", "last_update": "2026-09-04", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06470282", "title": "Enfortumab Vedotin and Pembrolizumab Combined With Radiotherapy in Muscle Invasive Bladder Cancer", "status": "RECRUITING", "last_update": "2026-02-18", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06493552", "title": "Modular Trial of sEphB4-HSA in EphrinB2-High Solid Tumors", "status": "RECRUITING", "last_update": "2025-04-03", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06764095", "title": "Enfortumab Vedotin and Pembrolizumab With Cystectomy and/or Ureterectomy for Locally Advanced or Metastatic Bladder and Upper Urothelial Tract Cancer, CAST-AI Trial", "status": "RECRUITING", "last_update": "2026-02-12", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06809140", "title": "Enfortumab Vedotin Plus Pembrolizumab With Selective Bladder Sparing for Treatment of Muscle-invasive Bladder Cancer", "status": "RECRUITING", "last_update": "2026-08-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06823427", "title": "9MW2821 + Toripalimab vs 9MW2821 for 1st Line Locally Advanced or Metastatic Urothelial Carcinoma", "status": "RECRUITING", "last_update": "2025-03-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07020117", "title": "A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors", "status": "RECRUITING", "last_update": "2026-09-08", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07087860", "title": "Therapeutic Plasma Exchange With Enfortumab Vedotin and Pembrolizumab for Treatment of Bladder Cancers", "status": "RECRUITING", "last_update": "2026-05-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07129993", "title": "Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma", "status": "RECRUITING", "last_update": "2026-08-20", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07218380", "title": "A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract", "status": "RECRUITING", "last_update": "2026-08-21", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07232602", "title": "KEYMAKER-U04 Substudy 04D: A Clinical Study of New Treatments Given With Enfortumab Vedotin and Pembrolizumab in People With Urothelial Cancer (MK-3475-04D/KEYMAKER-U04)", "status": "RECRUITING", "last_update": "2026-09-01", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07421700", "title": "Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer", "status": "RECRUITING", "last_update": "2026-08-17", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07475806", "title": "A Study to Find Out if Enfortumab Vedotin Given With Pembrolizumab Helps People With Muscle-invasive Bladder Cancer Keep Their Bladder", "status": "RECRUITING", "last_update": "2026-08-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07492628", "title": "Dual-Target Nectin-4/HER2 CAR-NK Cells in Advanced Urothelial Carcinoma", "status": "RECRUITING", "last_update": "2026-03-25", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07548476", "title": "Acupuncture and Exercise for EV-Pembro-Induced Peripheral Neuropathy", "status": "RECRUITING", "last_update": "2026-09-10", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07566156", "title": "Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invasive Bladder Cancer (EV-309)", "status": "RECRUITING", "last_update": "2026-09-11", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07579195", "title": "Consolidative Therapy After EV + Pembrolizumab in Muscle Invasive Bladder Cancer, REINFORCE Trial", "status": "RECRUITING", "last_update": "2026-08-25", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07647289", "title": "EV + Toripalimab vs GC as Neoadjuvant Therapy in Locally Advanced/High-Risk MIBC", "status": "RECRUITING", "last_update": "2026-06-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07720284", "title": "An Open-label Study to Investigate the Efficacy and Safety of Dato-DXd + Rilvegostomig vs SoC in Adult Participants With High-risk MIUC", "status": "RECRUITING", "last_update": "2026-07-22", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03219333", "title": "A Study of Enfortumab Vedotin for Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer", "status": "COMPLETED", "last_update": "2024-08-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03288545", "title": "A Study of Enfortumab Vedotin Alone or With Other Therapies for Treatment of Urothelial Cancer", "status": "TERMINATED", "last_update": "2026-03-24", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03474107", "title": "A Study to Evaluate Enfortumab Vedotin Versus (vs) Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer (EV-301)", "status": "COMPLETED", "last_update": "2026-01-09", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03606174", "title": "A Phase 2 Study of Sitravatinib in Combination With PD-(L)1 Checkpoint Inhibitor Regimens in Patients With Advanced or Metastatic Urothelial Carcinoma", "status": "TERMINATED", "last_update": "2023-08-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03869190", "title": "Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatments and Combinations in Patients With Urothelial Carcinoma (MORPHEUS-UC)", "status": "TERMINATED", "last_update": "2026-08-03", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03924895", "title": "Perioperative Pembrolizumab (MK-3475) Plus Cystectomy or Perioperative Pembrolizumab Plus Enfortumab Vedotin Plus Cystectomy Versus Cystectomy Alone in Participants Who Are Cisplatin-ineligible or Decline Cisplatin With Muscle-invasive Bladder Cancer (MK-3475-905/KEYNOTE-905/EV-303)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-30", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04561362", "title": "Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced Malignancies", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-11-14", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04700124", "title": "Perioperative Enfortumab Vedotin (EV) Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Chemotherapy for Cisplatin-Eligible Muscle Invasive Bladder Cancer (MIBC) (MK-3475-B15/ KEYNOTE-B15 / EV-304)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-16", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04960709", "title": "Treatment Combination of Durvalumab, Tremelimumab and Enfortumab Vedotin or Durvalumab and Enfortumab Vedotin in Patients With Muscle Invasive Bladder Cancer Ineligible to Cisplatin or Who Refuse Cisplatin", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-04", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04963153", "title": "Testing Combination Erdafitinib and Enfortumab Vedotin in Metastatic Bladder Cancer After Treatment With Chemotherapy and Immunotherapy", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-31", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05014139", "title": "A Study of Intravesical Enfortumab Vedotin For Treatment of Patients With Non-muscle Invasive Bladder Cancer (NMIBC)", "status": "TERMINATED", "last_update": "2025-11-20", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05524545", "title": "A Study of Evorpacept (ALX148) With Enfortumab Vedotin for Subjects With Urothelial Carcinoma (ASPEN-07)", "status": "COMPLETED", "last_update": "2025-07-25", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06204614", "title": "Drug Screening Using IMD in Bladder Cancer", "status": "ENROLLING_BY_INVITATION", "last_update": "2026-05-18", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06238479", "title": "A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06305767", "title": "A Clinical Study of Intismeran Autogene (V940) Treatment and Pembrolizumab in People With Bladder Cancer (V940-005/INTerpath-005)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-01-13", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07218003", "title": "A Phase 1/1b of RNDO-564 Single Agent or in Combination With Pembrolizumab in Bladder Cancer and Other Solid Tumors Associated With Nectin-4", "status": "ENROLLING_BY_INVITATION", "last_update": "2026-06-11", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07346053", "title": "The Impact of Time-of-day Administration of EV/P on Objective Response Rate in Adults With Advanced Bladder Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2026-01-16", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07643519", "title": "Neoadjuvant Enfortumab Vedotin Plus Pembrolizumab in Muscle-Invasive Bladder Cancer and Upper Tract Urothelial Carcinoma", "status": "NOT_YET_RECRUITING", "last_update": "2026-06-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07662863", "title": "Sacituzumab Tirumotecan vs MMAE-ADCs in Advanced Urothelial Carcinoma (FUSCC-SPARE-UC-01)", "status": "NOT_YET_RECRUITING", "last_update": "2026-06-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07663747", "title": "Enfortumab Vedotin + Pembrolizumab Induction to Spare the Bladder in MIBC", "status": "NOT_YET_RECRUITING", "last_update": "2026-06-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07667335", "title": "Enfortumab Vedotin, Pembrolizumab and Quemliclustat for the Treatment of Unresectable Locally Advanced and Metastatic Urothelial Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2026-09-04", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07690878", "title": "PTC-guided Neoadjuvant Therapy For Muscle-invasive Bladder Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2026-07-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ], "cell_therapy": { "n": 1, "n_observational": 0, "n_active": 1, "n_withdrawn": 0, "trials": [ { "nct": "NCT07492628", "title": "Dual-Target Nectin-4/HER2 CAR-NK Cells in Advanced Urothelial Carcinoma", "status": "RECRUITING", "last_update": "2026-03-25", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ] }, "synonyms_searched": [ "Nectin-4", "NECTIN4", "enfortumab", "Padcev" ] }, "TROP2": { "n": 23, "n_observational": 1, "n_active": 19, "n_withdrawn": 0, "trials": [ { "nct": "NCT04724018", "title": "Sacituzumab Govitecan Plus EV in Metastatic UC", "status": "RECRUITING", "last_update": "2025-11-04", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05833867", "title": "Adaptive RADiation Therapy With Concurrent Sacituzumab Govitecan (SG) for Muscle Invasive Bladder Cancer", "status": "RECRUITING", "last_update": "2026-07-20", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06161532", "title": "Sacituzumab Govitecan With or Without Atezolizumab Immunotherapy in Rare Genitourinary Tumors (SMART) Such as High Grade Neuroendocrine Carcinomas, Adenocarcinoma, and Squamous Cell Bladder/Urinary Tract Cancer, Renal Medullary Carcinoma and Penile C...", "status": "RECRUITING", "last_update": "2026-08-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06341478", "title": "Investigator Grant (IG) 2022 27746", "status": "RECRUITING", "last_update": "2024-04-02", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06637423", "title": "A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Patients With Bladder Cancer (MK-2870-027)", "status": "RECRUITING", "last_update": "2026-08-28", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06682728", "title": "Adjuvant Sacituzumab Govitecan and Nivolumab in Muscle-Invasive Urothelial Carcinoma at High-Risk Recurrence", "status": "RECRUITING", "last_update": "2026-04-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06851663", "title": "Trop2-targeted immunoPET Imaging of Solid Tumors", "status": "RECRUITING", "last_update": "2026-05-29", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07419295", "title": "A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031)", "status": "RECRUITING", "last_update": "2026-09-11", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07720284", "title": "An Open-label Study to Investigate the Efficacy and Safety of Dato-DXd + Rilvegostomig vs SoC in Adult Participants With High-risk MIUC", "status": "RECRUITING", "last_update": "2026-07-22", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01631552", "title": "Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer", "status": "COMPLETED", "last_update": "2021-08-12", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03869190", "title": "Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatments and Combinations in Patients With Urothelial Carcinoma (MORPHEUS-UC)", "status": "TERMINATED", "last_update": "2026-08-03", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04579224", "title": "Comparing the New Anti-cancer Drug Eribulin With Chemotherapy Against the Usual Chemotherapy Alone in Metastatic Urothelial Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-04", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04794699", "title": "Study of IDE397 in Participants With Solid Tumors Harboring MTAP Deletion", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-04-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04863885", "title": "Combination of Ipi/Nivo Plus Sacituzumab Govitecan in Metastatic Cisplatin Ineligible Urothelial Carcinoma Patients", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-12-17", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05226117", "title": "Sacituzumab Govitecan, Preceding Radical Cystectomy, in Treating Patients With Muscle-invasive Bladder Cancer", "status": "COMPLETED", "last_update": "2026-03-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05327530", "title": "A Study of the Safety and Efficacy of Various Combinations of Avelumab as Therapy in Locally Advanced or Metastatic Urothelial Carcinoma (JAVELIN Bladder Medley)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05535218", "title": "Pembrolizumab-Sacituzumab Govitecan Combination to Treat High-risk, Localized Bladder Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-04-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05581589", "title": "Sacituzumab Govitecan Before Radical Cystectomy for the Treatment of Non-Urothelial Muscle Invasive Bladder Cancer", "status": "TERMINATED", "last_update": "2026-04-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06133517", "title": "PeRioperative Immunotherapy Combined With Sacituzumab Govitecan in Muscle Invasive blAdder Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-03-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06204614", "title": "Drug Screening Using IMD in Bladder Cancer", "status": "ENROLLING_BY_INVITATION", "last_update": "2026-05-18", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06528483", "title": "Bladder Preservation With Sacituzumab Govitecan + Zimberelimab for Muscle-Invasive Bladder Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2024-07-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07662863", "title": "Sacituzumab Tirumotecan vs MMAE-ADCs in Advanced Urothelial Carcinoma (FUSCC-SPARE-UC-01)", "status": "NOT_YET_RECRUITING", "last_update": "2026-06-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07800507", "title": "Trop2-Targeted Near-Infrared Fluorescence Imaging-Guided Precise Resection of Non-Muscle Invasive Bladder Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2026-09-02", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" } ], "cell_therapy": { "n": 0, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [] }, "synonyms_searched": [ "TROP2", "TACSTD2", "sacituzumab", "Trodelvy" ] }, "PD-L1": { "n": 161, "n_observational": 11, "n_active": 66, "n_withdrawn": 9, "trials": [ { "nct": "NCT04106115", "title": "DURvalumab in Combination With S-488210/S-488211 vAccine in Non-muscle Invasive Bladder CancEr", "status": "RECRUITING", "last_update": "2026-06-11", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04585750", "title": "The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)", "status": "RECRUITING", "last_update": "2026-08-10", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05000294", "title": "Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types", "status": "RECRUITING", "last_update": "2026-07-13", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05267626", "title": "Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2R\u03b1 Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer", "status": "RECRUITING", "last_update": "2026-07-30", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05312671", "title": "Atezolizumab Plus Etoposide and Platinum in Small Cell Bladder Cancer", "status": "RECRUITING", "last_update": "2026-06-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05944237", "title": "HTL0039732 in Participants With Advanced Solid Tumours", "status": "RECRUITING", "last_update": "2025-06-08", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06022029", "title": "A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.", "status": "RECRUITING", "last_update": "2025-12-24", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06041503", "title": "Enfortumab Vedotin With or Without Pembrolizumab in Rare Genitourinary Tumors (E-VIRTUE)", "status": "RECRUITING", "last_update": "2026-08-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06161532", "title": "Sacituzumab Govitecan With or Without Atezolizumab Immunotherapy in Rare Genitourinary Tumors (SMART) Such as High Grade Neuroendocrine Carcinomas, Adenocarcinoma, and Squamous Cell Bladder/Urinary Tract Cancer, Renal Medullary Carcinoma and Penile C...", "status": "RECRUITING", "last_update": "2026-08-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06214572", "title": "Radiation Therapy in Unresectable Gall Bladder Cancer", "status": "RECRUITING", "last_update": "2025-04-11", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06228066", "title": "Lurbinectedin With or Without Avelumab in Small Cell Carcinoma of the Bladder (LASER)", "status": "RECRUITING", "last_update": "2026-08-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06263153", "title": "Futibatinib in Combination With Durvalumab Prior to Cystectomy for the Treatment of Muscle-Invasive Bladder Cancer Patients Who Are Ineligible for Cisplatin-based Therapy", "status": "RECRUITING", "last_update": "2025-12-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06444815", "title": "A Study of VET3-TGI in Patients With Solid Tumors", "status": "RECRUITING", "last_update": "2026-04-07", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06503614", "title": "A Trial of Durvalumab (MEDI4736) Plus Monalizumab in Non-Muscle-Invasive Bladder Cancer", "status": "RECRUITING", "last_update": "2026-04-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06820255", "title": "DDR Genes Alteration and Response to Platinum-based Chemotherapy in Advanced Urothelial Cancer.", "status": "RECRUITING", "last_update": "2025-02-11", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06892860", "title": "Comparing 3 vs 6 Cycles of Platinum-based Chemotherapy Prior to Maintenance Avelumab in Advanced Urothelial Cancer", "status": "RECRUITING", "last_update": "2026-05-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06960577", "title": "Perioperative Durvalumab With Neoadjuvant ddMVAC or Gemcitabine/Cisplatin in Patients With Muscle-invasive Bladder Cancer (NIAGARA-2)", "status": "RECRUITING", "last_update": "2026-08-04", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06963346", "title": "Study Investigating Intravesical HDAC Inhibition to Improve Response to Immuno-Oncology Agents", "status": "RECRUITING", "last_update": "2026-07-30", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07140315", "title": "DK222 Study at Hopkins", "status": "RECRUITING", "last_update": "2026-07-28", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07720284", "title": "An Open-label Study to Investigate the Efficacy and Safety of Dato-DXd + Rilvegostomig vs SoC in Adult Participants With High-risk MIUC", "status": "RECRUITING", "last_update": "2026-07-22", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01772004", "title": "Avelumab in Metastatic or Locally Advanced Solid Tumors (JAVELIN Solid Tumor)", "status": "COMPLETED", "last_update": "2021-12-20", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02091141", "title": "My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors", "status": "COMPLETED", "last_update": "2024-07-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02108652", "title": "A Study of Atezolizumab in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer (Cohort 2)", "status": "COMPLETED", "last_update": "2024-03-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02143804", "title": "Safety and Efficacy of CG0070 Oncolytic Virus Regimen in Patients With High Grade Non-Muscle Invasive Bladder Cancer", "status": "WITHDRAWN", "last_update": "2026-04-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02256436", "title": "A Study of Pembrolizumab (MK-3475) Versus Paclitaxel, Docetaxel, or Vinflunine for Participants With Advanced Urothelial Cancer (MK-3475-045/KEYNOTE-045)", "status": "COMPLETED", "last_update": "2021-09-20", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02302807", "title": "A Study of Atezolizumab Compared With Chemotherapy in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer [IMvigor211]", "status": "COMPLETED", "last_update": "2019-08-01", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02335424", "title": "Study of Pembrolizumab (MK-3475) in Participants With Advanced Urothelial Cancer (MK-3475-052/KEYNOTE-052)", "status": "COMPLETED", "last_update": "2023-03-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02451423", "title": "Neoadjuvant Atezolizumab in Localized Bladder Cancer", "status": "COMPLETED", "last_update": "2024-05-31", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02527434", "title": "Study of Tremelimumab in Patients With Advanced Solid Tumors", "status": "COMPLETED", "last_update": "2023-11-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02543645", "title": "A Study of Varlilumab and Atezolizumab in Patients With Advanced Cancer", "status": "TERMINATED", "last_update": "2018-04-30", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02546661", "title": "Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Phase 1b Study in Pts w/ Muscle Invasive Bladder Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-12-29", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02554812", "title": "A Study Of Avelumab In Combination With Other Cancer Immunotherapies In Advanced Malignancies (JAVELIN Medley)", "status": "TERMINATED", "last_update": "2024-07-30", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02603432", "title": "A Study Of Avelumab In Patients With Locally Advanced Or Metastatic Urothelial Cancer (JAVELIN Bladder 100)", "status": "COMPLETED", "last_update": "2024-03-27", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02625961", "title": "Study of Pembrolizumab (MK-3475) and Pembrolizumab With Other Investigational Agents in Participants With High Risk Non-muscle Invasive Bladder Cancer (MK-3475-057/KEYNOTE-057)", "status": "TERMINATED", "last_update": "2026-08-31", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02643303", "title": "A Study of Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible Cancers", "status": "COMPLETED", "last_update": "2022-12-02", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02662309", "title": "Preoperative MPDL3280A in Transitional Cell Carcinoma of the Bladder", "status": "COMPLETED", "last_update": "2025-03-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02792192", "title": "Safety and Pharmacology Study of Atezolizumab Alone and in Combination With Bacille Calmette-Gu\u00e9rin (BCG) in High-Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) Participants", "status": "TERMINATED", "last_update": "2021-10-28", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02807636", "title": "Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma", "status": "COMPLETED", "last_update": "2025-02-24", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02812420", "title": "Durvalumab and Tremelimumab in Treating Patients With Muscle-Invasive, High-Risk Urothelial Cancer That Cannot Be Treated With Cisplatin-Based Therapy Before Surgery", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-03-05", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02844816", "title": "Atezolizumab in Treating Patients With Recurrent BCG-Unresponsive Non-muscle Invasive Bladder Cancer", "status": "COMPLETED", "last_update": "2025-05-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02891161", "title": "Durvalumab And Radiation Therapy Followed by Adjuvant Durvalumab in Patients With Urothelial Cancer (T2-4 N0-2 M0) of the Bladder", "status": "TERMINATED", "last_update": "2024-11-27", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02901548", "title": "Phase 2 Durvalumab (Medi4736) for Bacillus Calmette-Gu\u00e9rin (BCG) Refactory Urothelial Carcinoma in Situ of the Bladder", "status": "TERMINATED", "last_update": "2022-07-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02903914", "title": "Arginase Inhibitor INCB001158 as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors", "status": "COMPLETED", "last_update": "2025-08-05", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02925533", "title": "Ph 1B B-701 in Combination With Pembrolizumab in Metastatic Transitional Cell Carcinoma of the Urothelial Tract", "status": "TERMINATED", "last_update": "2017-06-27", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02951767", "title": "A Study of Atezolizumab in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer (Cohort 1)", "status": "COMPLETED", "last_update": "2024-03-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02952989", "title": "A Safety Study of SGN-2FF for Patients With Advanced Solid Tumors", "status": "TERMINATED", "last_update": "2019-07-19", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02989584", "title": "A Phase II Study of Atezolizumab in Combination With Cisplatin + Gemcitabine Before Surgery to Remove the Bladder Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-01-07", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03007719", "title": "Functional Imaging of T-Cell Activation With [18F]F-AraG in Urothelial Carcinoma Patients Receiving Neoadjuvant Therapy or Patients With Cancer Receiving Standard of Care Anti-PD-1/L1", "status": "TERMINATED", "last_update": "2020-01-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03093922", "title": "A Study of Two Dosing Schedules of Atezolizumab in Combination With Gemcitabine and Cisplatin as First-Line Treatment for Metastatic Bladder Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-04-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03113266", "title": "Safety and Efficacy of Toripalimab for Patients With Locally Advanced or Metastatic Bladder Urothelial Carcinoma", "status": "UNKNOWN", "last_update": "2020-09-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03150836", "title": "Radiation Therapy and Durvalumab, With or Without Tremelimumab, in Patients With Bladder Cancer", "status": "WITHDRAWN", "last_update": "2017-10-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03170960", "title": "Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-08-17", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03179943", "title": "Atezolizumab + Guadecitabine in Patients With Checkpoint Inhibitor Refractory or Resistant Urothelial Carcinoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2021-11-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03234153", "title": "Neoadjuvant Immunotherapy With Durvalumab and Tremelimumab for Bladder Cancer Patients Ineligible for Cisplatin", "status": "TERMINATED", "last_update": "2020-06-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03237780", "title": "Atezolizumab With or Without Eribulin Mesylate in Treating Patients With Recurrent Locally Advanced or Metastatic Urothelial Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-31", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03258593", "title": "Durvalumab and Vicineum in Subjects With High-Grade Non-Muscle-Invasive Bladder Cancer Previously Treated With Bacillus Calmette-Guerin (BCG)", "status": "COMPLETED", "last_update": "2026-08-25", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03289962", "title": "A Study of Autogene Cevumeran (RO7198457) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors", "status": "COMPLETED", "last_update": "2026-06-08", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03317158", "title": "Modern Immunotherapy in BCG-Unresponsive, BCG-Relapsing and High Risk BCG-Naive Non-Muscle Invasive Urothelial Carcinoma of the Bladder", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-15", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03324282", "title": "First-line Gemcitabine/Cisplatin +/- Avelumab in Locally Advanced or Metastatic Bladder Carcinoma", "status": "TERMINATED", "last_update": "2026-05-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03359239", "title": "Atezolizumab Given in Combination With a Personalized Vaccine in Patients With Urothelial Cancer", "status": "COMPLETED", "last_update": "2023-05-16", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03406650", "title": "Neoadjuvant and Adjuvant Durvalumab in Combination With Neoadjuvant Chemotherapy in Patients With Operable Urothelial Cancer.", "status": "COMPLETED", "last_update": "2025-05-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03430895", "title": "Evaluating Immune Therapy, Durvalumab (MEDI4736) With Tremelimumab for Metastatic, Non-transitional Cell Carcinoma of the Urinary Tract", "status": "COMPLETED", "last_update": "2021-12-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03459846", "title": "A Study of Durvalumab Alone and Durvalumab+Olaparib in Advanced, Platinum-Ineligible Bladder Cancer (BAYOU)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03464032", "title": "A Study of BCD-135 in Patients With Advanced Solid Tumors", "status": "UNKNOWN", "last_update": "2018-03-13", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03472274", "title": "Durvalumab (MEDI4736) and TREmelimumab in NEOadjuvant Bladder Cancer Patients (DUTRENEO)", "status": "COMPLETED", "last_update": "2023-04-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03472560", "title": "A Study of Avelumab in Combination With Axitinib In Non-Small Cell Lung Cancer (NSCLC) or Urothelial Cancer (Javelin Medley VEGF)", "status": "TERMINATED", "last_update": "2024-04-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03473574", "title": "Durvalumab and Tremelimumab With Gemcitabine or Gemcitabine/Cisplatin Compared to Gemcitabine/Cisplatin in CCA Patients", "status": "COMPLETED", "last_update": "2023-06-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03473756", "title": "Phase 1b/2 Study of Rogaratinib (BAY1163877) in Combination With Atezolizumab in Urothelial Carcinoma", "status": "COMPLETED", "last_update": "2025-04-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03498196", "title": "A Window of Opportunity Trial: Avelumab in Non-metastatic Muscle Invasive Bladder Cancer", "status": "TERMINATED", "last_update": "2020-08-24", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03513952", "title": "Atezolizumab and CYT107 in Treating Participants With Locally Advanced, Inoperable, or Metastatic Urothelial Carcinoma", "status": "COMPLETED", "last_update": "2024-07-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03528694", "title": "Assessment of Efficacy and Safety of Durvalumab Plus BCG Compared to the Standard Therapy With BCG in Non-muscle Invasive Bladder Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-07", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03534492", "title": "Durvalumab Plus Olaparib Administered Prior to Surgery of Resectable Urothelial Bladder Cancer (NEODURVARIB)", "status": "COMPLETED", "last_update": "2020-04-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03577132", "title": "The Efficacy of Neoadjuvant Atezolizumab Treatment in Patients With Advanced Urothelial Bladder Cancer", "status": "UNKNOWN", "last_update": "2018-07-31", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03601455", "title": "Radiation Therapy and Durvalumab With or Without Tremelimumab in Treating Participants With Unresectable, Locally Advanced, or Metastatic Bladder Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03606174", "title": "A Phase 2 Study of Sitravatinib in Combination With PD-(L)1 Checkpoint Inhibitor Regimens in Patients With Advanced or Metastatic Urothelial Carcinoma", "status": "TERMINATED", "last_update": "2023-08-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03617913", "title": "Avelumab in Combination With Fluorouracil and Mitomycin or Cisplatin and Radiation Therapy in Treating Participants With Muscle-Invasive Bladder Cancer", "status": "COMPLETED", "last_update": "2023-01-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03620435", "title": "Trimodal Therapy Plus Atezolizumab in Muscle-invasive Bladder Cancer", "status": "UNKNOWN", "last_update": "2018-08-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03628716", "title": "CV301 Combined With PD-1/L1 Blockade in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer", "status": "COMPLETED", "last_update": "2022-04-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03637803", "title": "Live Biotherapeutic Product MRx0518 and Pembrolizumab Combination Study in Solid Tumors", "status": "TERMINATED", "last_update": "2023-06-01", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03650348", "title": "PRS-343 in Combination With Atezolizumab in HER2-Positive Solid Tumors", "status": "COMPLETED", "last_update": "2024-04-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03674424", "title": "Avelumab as Neoadjuvant Therapy in Subjects With Urothelial Muscle Invasive Bladder Cancers (AURA Trial)", "status": "COMPLETED", "last_update": "2025-02-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03682068", "title": "Study of Durvalumab Given With Chemotherapy, Durvalumab in Combination With Tremelimumab Given With Chemotherapy, or Chemotherapy in Patients With Unresectable Urothelial Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-20", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03693014", "title": "A Study of Several Radiation Doses for Patients With Progression on Immunotherapy/Checkpoint Inhibitors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03697850", "title": "Atezolizumab After Chemo-radiotherapy for MIBC Patients Not Eligible for Radical Cystectomy", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-11-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03702179", "title": "Durvalumab Plus Tremelimumab With Concurrent Radiotherapy for Localized Muscle Invasive Bladder Cancer Treated With a Selective Bladder Preservation Approach", "status": "COMPLETED", "last_update": "2024-12-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03711032", "title": "Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (MK-3475-676/KEYNOTE-676)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-01", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03715985", "title": "Personalized Neo-antigen Vaccine in Advanced Solid Tumors (NeoPepVac)", "status": "UNKNOWN", "last_update": "2022-01-11", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03732677", "title": "Durvalumab+ Gemcitabine/Cisplatin (Neoadjuvant Treatment) and Durvalumab (Adjuvant Treatment) in Patients With MIBC", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-17", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03744793", "title": "Pemetrexed and Avelumab in Treating Patients With MTAP-Deficient Metastatic Urothelial Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03747419", "title": "Avelumab and Radiation in Muscle-Invasive Bladder Cancer", "status": "TERMINATED", "last_update": "2025-10-31", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03759496", "title": "Efficacy of Durvalumab in Non-muscle-invasive Bladder Cancer", "status": "UNKNOWN", "last_update": "2022-03-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03768570", "title": "Trimodality Therapy With/Out Durvalumab to Treat Patients With Muscle-Invasive Bladder Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03773666", "title": "A Feasibility Study of Durvalumab +/- Oleclumab as Neoadjuvant Therapy for Muscle-invasive Bladder Cancer (BLASST-2)", "status": "COMPLETED", "last_update": "2022-09-13", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03775265", "title": "Chemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-28", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03785925", "title": "A Single-Arm Study of Bempegaldesleukin (NKTR-214) Plus Nivolumab in Cisplatin Ineligible Patients Who Have Locally Advanced or Metastatic Urothelial Cancer", "status": "COMPLETED", "last_update": "2023-03-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03799835", "title": "Atezolizumab Plus One-year BCG Bladder Instillation in BCG-naive High-risk Non-muscle Invasive Bladder Cancer Patients", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2024-12-11", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03824691", "title": "hARnessing CAbozantinib and Durvalumab Immuno-oncology Association: ARCADIA Study\"", "status": "UNKNOWN", "last_update": "2021-02-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03869190", "title": "Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatments and Combinations in Patients With Urothelial Carcinoma (MORPHEUS-UC)", "status": "TERMINATED", "last_update": "2026-08-03", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03892642", "title": "Avelumab Plus Bacille Calmette-Guerin (BCG) in Patients With Non-muscle Invasive Bladder Cancer", "status": "COMPLETED", "last_update": "2024-02-14", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03912818", "title": "Durvalumab and Standard Chemotherapy Before Surgery in Treating Patients With Variant Histology Bladder Cancer", "status": "TERMINATED", "last_update": "2023-09-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03915405", "title": "KHK2455 (IDO Inhibitor) Plus Avelumab in Adult Subjects With Advanced Bladder Cancer", "status": "TERMINATED", "last_update": "2024-04-25", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03915678", "title": "Atezolizumab Combined With BDB001 AnD Immunogenic Radiotherapy in Patients With Advanced Solid Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03924856", "title": "Perioperative Pembrolizumab (MK-3475) Plus Neoadjuvant Chemotherapy Versus Perioperative Placebo Plus Neoadjuvant Chemotherapy for Cisplatin-eligible Muscle-invasive Bladder Cancer (MIBC) (MK-3475-866/KEYNOTE-866)", "status": "COMPLETED", "last_update": "2026-07-22", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03950362", "title": "Bladder PREserVation by RadioTherapy and Immunotherapy in BCG Unresponsive Non-muscle Invasive Bladder Cancer", "status": "UNKNOWN", "last_update": "2019-05-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03983954", "title": "Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumor, Including a Cohort Expansion in Esophageal Cancer.", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-11-28", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03999658", "title": "A Study of STI-3031 (an Anti-PD-L1 Antibody) in Patients With Selected Relapsed/Refractory Malignancies", "status": "WITHDRAWN", "last_update": "2023-05-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04004221", "title": "Study of Tislelizumab in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer", "status": "COMPLETED", "last_update": "2024-10-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04004442", "title": "Avelumab in Combination With AVB-S6-500 in Patients With Advanced Urothelial Carcinoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-03-13", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04045613", "title": "Derazantinib and Atezolizumab in Patients With Urothelial Cancer", "status": "COMPLETED", "last_update": "2023-10-13", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04073160", "title": "TRIO Bladder: A Study of Durvalumab Plus Tremelimumab Followed by Concurrent Durvalumab Plus Bladder Radiation in Muscle-Invasive Bladder Cancer", "status": "WITHDRAWN", "last_update": "2020-07-07", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04101812", "title": "Pegylated Liposomal Doxorubicin, PD-1 in Treating Muscle Invasive Bladder Cancer", "status": "UNKNOWN", "last_update": "2019-09-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04134000", "title": "Atezolizumab and BCG in High Risk BCG na\u00efve Non-muscle Invasive Bladder Cancer (NMIBC) Patients (BladderGATE)", "status": "UNKNOWN", "last_update": "2024-05-21", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04138628", "title": "Treatment Of Metastatic Bladder Cancer at the Time Of Biochemical reLApse Following Radical Cystectomy", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-04-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04157985", "title": "Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors", "status": "COMPLETED", "last_update": "2025-12-11", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04165317", "title": "A Study of Sasanlimab in People With Non-muscle Invasive Bladder Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-01-22", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04186013", "title": "Efficacy of Atezolizumab Concurrent With Radiotherapy in Patients With Muscle-invasive Bladder c\u00e1ncer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2022-10-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04216290", "title": "A Study of Chemotherapy and Radiation Therapy Compared to Chemotherapy and Radiation Therapy Plus MEDI4736 (Durvalumab) Immunotherapy for Bladder Cancer Which Has Spread to the Lymph Nodes, INSPIRE Trial", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04260802", "title": "A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers", "status": "TERMINATED", "last_update": "2026-01-12", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04289779", "title": "Study of CAbozantinib in Combination with AtezolizumaB for Muscle-Invasive BladdEr Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2024-12-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04543110", "title": "Radiation and Durvalumab Immunotherapy As Neoadjuvant Treatment for MIBC", "status": "UNKNOWN", "last_update": "2023-03-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04579133", "title": "Neoadjuvant Durvalumab Alone Versus Durvalumab With Olaparib in Patients Ineligible for Cisplatin With Muscle-Invasive Urothelial Carcinoma of the Bladder Followed by Radical Cystectomy", "status": "TERMINATED", "last_update": "2021-06-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04579224", "title": "Comparing the New Anti-cancer Drug Eribulin With Chemotherapy Against the Usual Chemotherapy Alone in Metastatic Urothelial Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-04", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04602078", "title": "Study of Atezolizumab Combined With Split-dose Gemcitabine Plus Cisplatin in Urothelial Carcinoma", "status": "COMPLETED", "last_update": "2025-04-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04630730", "title": "Intravesical Recombinant BCG Followed by Perioperative Chemo-immunotherapy for Patients With MIBC", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-01-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04637594", "title": "Trying to Find the Correct Length of Treatment With Immune Checkpoint Therapy", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-03-20", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04660344", "title": "A Study of Atezolizumab Versus Placebo as Adjuvant Therapy in Participants With High-risk Muscle-invasive Bladder Cancer (MIBC) Who Are ctDNA Positive Following Cystectomy", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-03-27", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04700124", "title": "Perioperative Enfortumab Vedotin (EV) Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Chemotherapy for Cisplatin-Eligible Muscle Invasive Bladder Cancer (MIBC) (MK-3475-B15/ KEYNOTE-B15 / EV-304)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-16", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04701918", "title": "Cryoablation With Pembrolizumab Or Avelumab In Urothelial Carcinoma", "status": "COMPLETED", "last_update": "2026-01-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04713891", "title": "A Study of KF-0210 in Advanced Solid Tumors Patients", "status": "COMPLETED", "last_update": "2024-09-24", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04718584", "title": "the Efficacy and Safety of LDP in Patients With Urinary and Male Genital Tumors", "status": "COMPLETED", "last_update": "2026-07-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04848519", "title": "Immune Checkpoint Inhibitors With or Without Propranolol Hydrochloride In Patients With Urothelial Carcinoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-02-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04871529", "title": "Testing the Addition of an Anti-Cancer Immunotherapy Drug, Avelumab, to Gemcitabine and Carboplatin Chemotherapy Prior to Surgery in Muscle Invasive Urinary Tract Cancer vs. Surgery Alone in Patients Who Are Not Able to Receive Cisplatin Therapy (SWOG GAP TRIAL)", "status": "TERMINATED", "last_update": "2024-12-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04887831", "title": "Trilaciclib, a CDK 4/6 Inhibitor, in Patients With Advanced/Metastatic Bladder Cancer Receiving Chemotherapy Then Avelumab", "status": "TERMINATED", "last_update": "2025-09-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04902040", "title": "Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies", "status": "TERMINATED", "last_update": "2026-04-30", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04960709", "title": "Treatment Combination of Durvalumab, Tremelimumab and Enfortumab Vedotin or Durvalumab and Enfortumab Vedotin in Patients With Muscle Invasive Bladder Cancer Ineligible to Cisplatin or Who Refuse Cisplatin", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-04", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05007106", "title": "MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005)", "status": "COMPLETED", "last_update": "2025-08-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05061537", "title": "Study of PF-07263689 in Participants With Selected Advanced Solid Tumors", "status": "TERMINATED", "last_update": "2024-04-12", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05077709", "title": "IO102-IO103 in Combination With Pembrolizumab as First-line Treatment for Patients With Metastatic NSCLC, SCCHN, or mUBC", "status": "COMPLETED", "last_update": "2026-04-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05092958", "title": "Testing the Addition of the Anti-cancer Drug, Cabozantinib, to the Usual Immunotherapy Treatment, Avelumab, in Patients With Metastatic Urothelial Cancer, MAIN-CAV Study", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-12", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05120622", "title": "Trial of Local Cystoscopic Injection of Tremelimumab Plus Systemic Durvalumab for High Risk Non-Muscle Invasive Bladder Cancer", "status": "WITHDRAWN", "last_update": "2023-10-31", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05137262", "title": "A Phase II Multicenter Study of Chemotherapy Versus Chemotherapy Plus Durvalumab (MEDI 4736) in Patients With Lymph Node Positive Urothelial Carcinoma of the Bladder", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05239169", "title": "Immunotherapy With Durva and Treme With or Without Capecitabine in Adjuvant Treatment for Biliary Tract Cancer", "status": "COMPLETED", "last_update": "2025-05-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05253053", "title": "To Evaluate Efficacy and Safety of TT-00420 (Tinengotinib) as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors", "status": "COMPLETED", "last_update": "2025-06-12", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05259319", "title": "Study Evaluating the Safety and the Efficacy of Combination of Atezolizumab, Tiragolumab and and Stereotactic Body Radiation Therapy in Patients With Oligometastatic Multiorgan (IMMUNOs-SBRT)", "status": "UNKNOWN", "last_update": "2023-10-17", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05327530", "title": "A Study of the Safety and Efficacy of Various Combinations of Avelumab as Therapy in Locally Advanced or Metastatic Urothelial Carcinoma (JAVELIN Bladder Medley)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05401279", "title": "Bladder Sparing Treatment of Tislelizumab, Gemcitabine and Cisplatin for Patients With PD-L1 Positive Muscle Invasive Bladder Cancer", "status": "UNKNOWN", "last_update": "2022-08-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05429866", "title": "Immunological Variables Associated to ICI Toxicity in Cancer Patients", "status": "UNKNOWN", "last_update": "2023-03-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05564416", "title": "Testing Anti-Cancer Drugs Erdafitinib With or Without Atezolizumab in Patients With Localized Bladder Cancer Not Able to Receive Cisplatin Chemotherapy, NERA Trial", "status": "WITHDRAWN", "last_update": "2025-10-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05687721", "title": "Copanlisib and Avelumab as a Maintenance Therapy for Advanced Bladder Cancer", "status": "WITHDRAWN", "last_update": "2025-06-15", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05712356", "title": "A Study of LSTA1 When Added to Standard of Care Versus Standard of Care Alone in Patients With Advanced Solid Tumors", "status": "TERMINATED", "last_update": "2026-05-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05843448", "title": "IDO and PD-L1 Peptide Based Immune-Modulatory Therapeutic (IO102-IO103) in Combination With Pembrolizumab for BCG-Unresponsive or Intolerant, Non-Muscle Invasive Bladder Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-16", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05943106", "title": "BCG in Combination With Durvalumab in Adult BCG-na\u00efve, High-risk NMIBC Participants", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-13", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06090318", "title": "Milademetan in Combination With Atezolizumab in Patients With Advanced Solid Tumors With CDKN2A Loss", "status": "WITHDRAWN", "last_update": "2023-10-19", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06204614", "title": "Drug Screening Using IMD in Bladder Cancer", "status": "ENROLLING_BY_INVITATION", "last_update": "2026-05-18", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06225596", "title": "Study BT8009-230 in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06305767", "title": "A Clinical Study of Intismeran Autogene (V940) Treatment and Pembrolizumab in People With Bladder Cancer (V940-005/INTerpath-005)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-01-13", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06424717", "title": "Study of Avelumab and Tuvusertib in Participants With Advanced Urothelial Cancer That Has Progressed on Prior Anti-PD-(L)1 Therapy (JAVELIN DDRiver Bladder)", "status": "WITHDRAWN", "last_update": "2024-09-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06448364", "title": "A Study in Advanced/Metastatic Solid Tumors With the Study Medicine (PF-07329640) When Given Alone or In Combination", "status": "TERMINATED", "last_update": "2024-11-06", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06686381", "title": "Tetra-modality Bladder Preservation Strategies in Muscle-invasive Bladder Cancer: TURBT+ Chemo/Immunotherapy+ Radiation Therapy+ Maintenance Immunotherapy vs. W&W", "status": "NOT_YET_RECRUITING", "last_update": "2025-02-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07332351", "title": "Neoadjuvant Intravesical Nadofaragene Firadenovec With Gemcitabine, Cisplatin and Durvalumab for the Treatment of Muscle Invasive Bladder Cancer, TRIFECTA Trial", "status": "NOT_YET_RECRUITING", "last_update": "2026-06-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07625527", "title": "Is Prolonged Systemic Immunotherapy Necessary After Achieving Tumor-free Status in Patients With Extensive Transurethrally Unresectable Very-high-risk NMIBC?", "status": "NOT_YET_RECRUITING", "last_update": "2026-06-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ], "cell_therapy": { "n": 1, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT03785925", "title": "A Single-Arm Study of Bempegaldesleukin (NKTR-214) Plus Nivolumab in Cisplatin Ineligible Patients Who Have Locally Advanced or Metastatic Urothelial Cancer", "status": "COMPLETED", "last_update": "2023-03-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "synonyms_searched": [ "PD-L1", "atezolizumab", "avelumab", "durvalumab" ] }, "PD-1": { "n": 229, "n_observational": 7, "n_active": 116, "n_withdrawn": 8, "trials": [ { "nct": "NCT03866382", "title": "Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors", "status": "RECRUITING", "last_update": "2026-09-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04389632", "title": "A Study of Sigvotatug Vedotin in Advanced Solid Tumors", "status": "RECRUITING", "last_update": "2026-07-06", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04585750", "title": "The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)", "status": "RECRUITING", "last_update": "2026-08-10", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04724018", "title": "Sacituzumab Govitecan Plus EV in Metastatic UC", "status": "RECRUITING", "last_update": "2025-11-04", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04879329", "title": "A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2", "status": "RECRUITING", "last_update": "2026-07-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05072600", "title": "Pembrolizumab Monotherapy Following Tri-modality Treatment for Selected Patients With Muscle-invasive Bladder Cancer", "status": "RECRUITING", "last_update": "2022-01-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05086692", "title": "A Beta-only IL-2 ImmunoTherapY Study", "status": "RECRUITING", "last_update": "2025-07-09", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05126472", "title": "Study of 2141-V11 in People With Non-muscle Invasive Bladder Cancer That Did Not Respond to Standard Treatment", "status": "RECRUITING", "last_update": "2026-08-14", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05203913", "title": "Cisplatin, Nab-paclitaxel, Nivolumab With Radiotherapy After Resection of Non-Metastatic Muscle Invasive Bladder Cancer", "status": "RECRUITING", "last_update": "2024-10-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05239624", "title": "Enfortumab Vedotin and Pembrolizumab in People With Bladder Cancer", "status": "RECRUITING", "last_update": "2026-06-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05267626", "title": "Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2R\u03b1 Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer", "status": "RECRUITING", "last_update": "2026-07-30", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05614739", "title": "FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3", "status": "RECRUITING", "last_update": "2026-08-20", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05656235", "title": "Renal Retention in High Grade Upper Tract Urothelial Cancer", "status": "RECRUITING", "last_update": "2026-01-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05756569", "title": "Enfortumab Vedotin Plus Pembrolizumab for the Treatment of Locally Advanced or Metastatic Bladder Cancer of Variant Histology", "status": "RECRUITING", "last_update": "2026-07-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05879653", "title": "Pembrolizumab and EV With Radiation Therapy for MIBC Patients (PEVRAD)", "status": "RECRUITING", "last_update": "2025-08-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05944237", "title": "HTL0039732 in Participants With Advanced Solid Tumours", "status": "RECRUITING", "last_update": "2025-06-08", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05987241", "title": "Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study", "status": "RECRUITING", "last_update": "2026-09-11", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06022029", "title": "A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.", "status": "RECRUITING", "last_update": "2025-12-24", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06041503", "title": "Enfortumab Vedotin With or Without Pembrolizumab in Rare Genitourinary Tumors (E-VIRTUE)", "status": "RECRUITING", "last_update": "2026-08-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06228066", "title": "Lurbinectedin With or Without Avelumab in Small Cell Carcinoma of the Bladder (LASER)", "status": "RECRUITING", "last_update": "2026-08-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06253871", "title": "A Phase 1/1b Study of IAM1363 in HER2 Cancers", "status": "RECRUITING", "last_update": "2026-09-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06341478", "title": "Investigator Grant (IG) 2022 27746", "status": "RECRUITING", "last_update": "2024-04-02", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06470282", "title": "Enfortumab Vedotin and Pembrolizumab Combined With Radiotherapy in Muscle Invasive Bladder Cancer", "status": "RECRUITING", "last_update": "2026-02-18", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06493552", "title": "Modular Trial of sEphB4-HSA in EphrinB2-High Solid Tumors", "status": "RECRUITING", "last_update": "2025-04-03", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06545955", "title": "A Trial to Evaluate Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade BCG Unresponsive Non-muscle Invasive Bladder Cancer", "status": "RECRUITING", "last_update": "2026-08-06", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06571708", "title": "Gemcitabine/Cisplatin Plus Cemiplimab With or Without Fianlimab in Localized Muscle-invasive Bladder Cancer (NeoSTOP-IT)", "status": "RECRUITING", "last_update": "2025-09-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06586255", "title": "Adjuvant Concurrent Immunotherapy and Radiotherapy for the Treatment of Bladder Cancer", "status": "RECRUITING", "last_update": "2026-05-14", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06638931", "title": "Agnostic Therapy in Rare Solid Tumors", "status": "RECRUITING", "last_update": "2026-04-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06682728", "title": "Adjuvant Sacituzumab Govitecan and Nivolumab in Muscle-Invasive Urothelial Carcinoma at High-Risk Recurrence", "status": "RECRUITING", "last_update": "2026-04-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06696742", "title": "PD1 Inhibitors Combined With Clostridium Butyricum for Urothelial Carcinoma", "status": "RECRUITING", "last_update": "2024-11-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06764095", "title": "Enfortumab Vedotin and Pembrolizumab With Cystectomy and/or Ureterectomy for Locally Advanced or Metastatic Bladder and Upper Urothelial Tract Cancer, CAST-AI Trial", "status": "RECRUITING", "last_update": "2026-02-12", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06770582", "title": "Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial", "status": "RECRUITING", "last_update": "2026-09-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06809140", "title": "Enfortumab Vedotin Plus Pembrolizumab With Selective Bladder Sparing for Treatment of Muscle-invasive Bladder Cancer", "status": "RECRUITING", "last_update": "2026-08-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06823427", "title": "9MW2821 + Toripalimab vs 9MW2821 for 1st Line Locally Advanced or Metastatic Urothelial Carcinoma", "status": "RECRUITING", "last_update": "2025-03-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06972615", "title": "Intravesical Chemotherapy in Combination With Systemic Pembrolizumab in NMIBC Unresponsive or Exposed to BCG Therapy", "status": "RECRUITING", "last_update": "2026-05-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06983210", "title": "Clinical Trial of AM80 in Combination With Gemcitabine, Cisplatin, and Nivolumab in Patients With Urothelial Carcinoma", "status": "RECRUITING", "last_update": "2025-08-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07025174", "title": "Sequential Anti-Angiogenic Therapy After Immunotherapy in Advanced Biliary Tract Cancer", "status": "RECRUITING", "last_update": "2025-06-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07061964", "title": "Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT Trial", "status": "RECRUITING", "last_update": "2026-08-31", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07087860", "title": "Therapeutic Plasma Exchange With Enfortumab Vedotin and Pembrolizumab for Treatment of Bladder Cancers", "status": "RECRUITING", "last_update": "2026-05-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07129993", "title": "Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma", "status": "RECRUITING", "last_update": "2026-08-20", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07140315", "title": "DK222 Study at Hopkins", "status": "RECRUITING", "last_update": "2026-07-28", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07218380", "title": "A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract", "status": "RECRUITING", "last_update": "2026-08-21", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07232602", "title": "KEYMAKER-U04 Substudy 04D: A Clinical Study of New Treatments Given With Enfortumab Vedotin and Pembrolizumab in People With Urothelial Cancer (MK-3475-04D/KEYMAKER-U04)", "status": "RECRUITING", "last_update": "2026-09-01", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07410676", "title": "EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 \u00b1 Pembrolizumab in Advanced Solid Tumors", "status": "RECRUITING", "last_update": "2026-02-18", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07421700", "title": "Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer", "status": "RECRUITING", "last_update": "2026-08-17", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07475806", "title": "A Study to Find Out if Enfortumab Vedotin Given With Pembrolizumab Helps People With Muscle-invasive Bladder Cancer Keep Their Bladder", "status": "RECRUITING", "last_update": "2026-08-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07548476", "title": "Acupuncture and Exercise for EV-Pembro-Induced Peripheral Neuropathy", "status": "RECRUITING", "last_update": "2026-09-10", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07566156", "title": "Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invasive Bladder Cancer (EV-309)", "status": "RECRUITING", "last_update": "2026-09-11", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07579195", "title": "Consolidative Therapy After EV + Pembrolizumab in Muscle Invasive Bladder Cancer, REINFORCE Trial", "status": "RECRUITING", "last_update": "2026-08-25", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07717242", "title": "Sun Yat-Sen Treatment Strategy for Enhancing Response in Muscle-invasive Bladder Cancer", "status": "RECRUITING", "last_update": "2026-07-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07720284", "title": "An Open-label Study to Investigate the Efficacy and Safety of Dato-DXd + Rilvegostomig vs SoC in Adult Participants With High-risk MIUC", "status": "RECRUITING", "last_update": "2026-07-22", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02043665", "title": "CVA21 and Pembrolizumab in NSCLC & Bladder Cancer (VLA-009 STORM/ KEYNOTE-200)", "status": "COMPLETED", "last_update": "2023-05-06", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02108652", "title": "A Study of Atezolizumab in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer (Cohort 2)", "status": "COMPLETED", "last_update": "2024-03-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02178722", "title": "Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers", "status": "COMPLETED", "last_update": "2022-02-14", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02256436", "title": "A Study of Pembrolizumab (MK-3475) Versus Paclitaxel, Docetaxel, or Vinflunine for Participants With Advanced Urothelial Cancer (MK-3475-045/KEYNOTE-045)", "status": "COMPLETED", "last_update": "2021-09-20", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02324582", "title": "MK-3475/BCG in High Risk Superficial Bladder Cancer", "status": "COMPLETED", "last_update": "2024-09-03", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02335424", "title": "Study of Pembrolizumab (MK-3475) in Participants With Advanced Urothelial Cancer (MK-3475-052/KEYNOTE-052)", "status": "COMPLETED", "last_update": "2023-03-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02346955", "title": "Study of CM-24 (MK-6018) Alone and In Combination With Pembrolizumab (MK-3475) in Participants With Selected Advanced or Recurrent Malignancies (MK-6018-001)", "status": "TERMINATED", "last_update": "2020-08-27", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02351739", "title": "Study of the Combination of ACP-196 and Pembrolizumab in Subjects With Platinum Resistant Urothelial Bladder Cancer", "status": "COMPLETED", "last_update": "2019-09-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02365766", "title": "Neoadjuvant Pembrolizumab in Combination With Gemcitabine Therapy in Cis-eligible/Ineligible UC Subjects", "status": "COMPLETED", "last_update": "2025-03-18", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02387996", "title": "A Study of Nivolumab in Participants With Metastatic or Unresectable Bladder Cancer", "status": "COMPLETED", "last_update": "2022-11-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02432963", "title": "Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-01-28", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02437370", "title": "Pembrolizumab and Docetaxel or Gemcitabine Hydrochloride in Treating Patients Urothelial Cancer", "status": "COMPLETED", "last_update": "2022-10-18", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02443324", "title": "A Study of Ramucirumab Plus Pembrolizumab in Participants With Gastric or GEJ Adenocarcinoma, NSCLC, Transitional Cell Carcinoma of the Urothelium, or Biliary Tract Cancer", "status": "COMPLETED", "last_update": "2024-07-31", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02465060", "title": "Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02496208", "title": "Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-10", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02500121", "title": "Testing the PD-1 Inhibitor Pembrolizumab as Maintenance Therapy After Initial Chemotherapy in Metastatic Bladder Cancer", "status": "COMPLETED", "last_update": "2022-09-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02553642", "title": "Relationship Between Tumor Mutation Burden and Predicted Neo-antigen Burden in Patients With Advanced Melanoma or Bladder Cancer Treated With Nivolumab or Nivolumab Plus Ipilimumab (CA209-260)", "status": "COMPLETED", "last_update": "2025-07-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02560636", "title": "Pembrolizumab in Muscle Invasive/Metastatic Bladder Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-01-06", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02581982", "title": "Paclitaxel and Pembrolizumab in Treating Patients With Refractory Metastatic Urothelial Cancer", "status": "COMPLETED", "last_update": "2023-01-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02619253", "title": "Phase I/Ib Study of Pembrolizumab With Vorinostat for Patients With Advanced Renal or Urothelial Cell Carcinoma", "status": "COMPLETED", "last_update": "2024-11-18", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02621151", "title": "Pembrolizumab (MK3475), Gemcitabine, and Concurrent Hypofractionated Radiation Therapy for Muscle-Invasive Urothelial Cancer of the Bladder", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-10-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02625961", "title": "Study of Pembrolizumab (MK-3475) and Pembrolizumab With Other Investigational Agents in Participants With High Risk Non-muscle Invasive Bladder Cancer (MK-3475-057/KEYNOTE-057)", "status": "TERMINATED", "last_update": "2026-08-31", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02632409", "title": "An Investigational Immuno-therapy Study of Nivolumab, Compared to Placebo, in Patients With Bladder or Upper Urinary Tract Cancer, Following Surgery to Remove the Cancer", "status": "COMPLETED", "last_update": "2026-07-30", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02662062", "title": "Pembrolizumab With Chemoradiotherapy as Treatment for Muscle Invasive Bladder Cancer", "status": "COMPLETED", "last_update": "2025-01-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02690558", "title": "Phase 2 Study of Pembrolizumab in Combination With Gemcitabine and Cisplatin as Neoadjuvant Therapy", "status": "COMPLETED", "last_update": "2026-03-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02717156", "title": "Multicohort Phase II Trial of sEphB4-HSA+Pembrolizumab in Solid Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02736266", "title": "Neoadjuvant Pembrolizumab for Muscle-invasive Urothelial Bladder Carcinoma", "status": "COMPLETED", "last_update": "2023-07-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02808143", "title": "Pembrolizumab and BCG Solution in Treating Patients With Recurrent Non-Muscle-Invasive Bladder Cancer", "status": "COMPLETED", "last_update": "2024-06-26", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02834013", "title": "Nivolumab and Ipilimumab in Treating Patients With Rare Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02845323", "title": "Neoadjuvant Nivolumab With and Without Urelumab in Cisplatin-Ineligible or Chemotherapy-refusing Patients With Muscle-Invasive Urothelial Carcinoma of the Bladder", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-04-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02863913", "title": "PD-1 Knockout Engineered T Cells for Muscle-invasive Bladder Cancer", "status": "WITHDRAWN", "last_update": "2019-03-06", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02886897", "title": "A Study of Combinations of D-CIK Immunotherapy And Anti-PD-1 In Refractory Solid Tumors", "status": "UNKNOWN", "last_update": "2016-09-01", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02897765", "title": "A Personal Cancer Vaccine (NEO-PV-01) w/ Nivolumab for Patients With Melanoma, Lung Cancer or Bladder Cancer", "status": "COMPLETED", "last_update": "2021-02-25", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02903914", "title": "Arginase Inhibitor INCB001158 as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors", "status": "COMPLETED", "last_update": "2025-08-05", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02925533", "title": "Ph 1B B-701 in Combination With Pembrolizumab in Metastatic Transitional Cell Carcinoma of the Urothelial Tract", "status": "TERMINATED", "last_update": "2017-06-27", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02951767", "title": "A Study of Atezolizumab in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer (Cohort 1)", "status": "COMPLETED", "last_update": "2024-03-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02952989", "title": "A Safety Study of SGN-2FF for Patients With Advanced Solid Tumors", "status": "TERMINATED", "last_update": "2019-07-19", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03007719", "title": "Functional Imaging of T-Cell Activation With [18F]F-AraG in Urothelial Carcinoma Patients Receiving Neoadjuvant Therapy or Patients With Cancer Receiving Standard of Care Anti-PD-1/L1", "status": "TERMINATED", "last_update": "2020-01-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03106610", "title": "Trial of Anti-PD-1 (Nivolumab) in Bladder Cancer Patients Recently Treated With Intravesical BCG Immunotherapy", "status": "TERMINATED", "last_update": "2018-05-24", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03113266", "title": "Safety and Efficacy of Toripalimab for Patients With Locally Advanced or Metastatic Bladder Urothelial Carcinoma", "status": "UNKNOWN", "last_update": "2020-09-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03123055", "title": "A Study of B-701 in Combination With Pembrolizumab in Treatment of Locally Advanced or Metastatic Urothelial Cell Carcinoma", "status": "TERMINATED", "last_update": "2020-03-18", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03167151", "title": "Pembrolizumab in Intermediate Risk Recurrent Non-muscle Invasive Bladder Cancer (NMIBC)", "status": "TERMINATED", "last_update": "2020-07-31", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03170960", "title": "Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-08-17", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03171025", "title": "Adjuvant Nivolumab Following Chemo-Radiation in Localized Muscle-Invasive Bladder Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-01-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03212651", "title": "Study Evaluating Neoadjuvant Pembrolizumab Monotherapy in Patients With Muscle-Invasive Bladder Cancer to Explore in Vivo the Mechanisms of Action of Pembrolizumab", "status": "COMPLETED", "last_update": "2023-01-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03229278", "title": "Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or Lymphoma", "status": "COMPLETED", "last_update": "2023-12-06", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03236935", "title": "Phase Ib of L-NMMA and Pembrolizumab", "status": "COMPLETED", "last_update": "2026-04-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03244384", "title": "Testing MK-3475 (Pembrolizumab) After Surgery for Localized Muscle-Invasive Bladder Cancer and Locally Advanced Urothelial Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-28", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03263039", "title": "Biomarkers in Urothelial Cancer Patients Treated With Pembrolizumab", "status": "UNKNOWN", "last_update": "2021-08-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03288545", "title": "A Study of Enfortumab Vedotin Alone or With Other Therapies for Treatment of Urothelial Cancer", "status": "TERMINATED", "last_update": "2026-03-24", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03294304", "title": "BLASST-1 (Bladder Cancer Signal Seeking Trial): Nivolumab, Gemcitabine, and Cisplatin in Treatment of Muscle Invasive Bladder Cancer (MIBC) Undergoing Cystectomy", "status": "COMPLETED", "last_update": "2021-12-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03311334", "title": "A Study of DSP-7888 Dosing Emulsion in Combination With Immune Checkpoint Inhibitors in Adult Patients With Advanced Solid Tumors", "status": "TERMINATED", "last_update": "2024-04-18", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03319745", "title": "Pembrolizumab in Treating Patients With Bladder Cancer Undergoing Radical Cystectomy", "status": "COMPLETED", "last_update": "2024-06-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03324282", "title": "First-line Gemcitabine/Cisplatin +/- Avelumab in Locally Advanced or Metastatic Bladder Carcinoma", "status": "TERMINATED", "last_update": "2026-05-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03329950", "title": "A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies", "status": "COMPLETED", "last_update": "2024-03-28", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03333616", "title": "Nivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03387761", "title": "Neo-Adjuvant Bladder Urothelial Carcinoma COmbination-immunotherapy", "status": "COMPLETED", "last_update": "2025-03-05", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03419130", "title": "Radiation Therapy and Pembrolizumab in Treating Patients With Localized Urothelial Bladder Cancer", "status": "WITHDRAWN", "last_update": "2018-12-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03421652", "title": "Nivolumab and RT in Treating Patients With Localized/Locally Advanced Urothelial Bladder Cancer Ineligible for Chemo", "status": "COMPLETED", "last_update": "2023-08-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03454451", "title": "CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers", "status": "COMPLETED", "last_update": "2023-12-21", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03504163", "title": "Pembrolizumab (MK-3475) and Bacillus Calmette-Gu\u00e9rin (BCG) as First-Line Treatment for High-Risk T1 Non-Muscle-Invasive Bladder Cancer (NMIBC) and High-Grade Non-Muscle-Invasive Upper Tract Urothelial Carcinoma (NMI-UTUC)]", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03518320", "title": "Safety and Tolerability of TAR-200 and Nivolumab in Subjects With Muscle-Invasive Bladder Cancer", "status": "TERMINATED", "last_update": "2024-08-27", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03519256", "title": "A Study of Nivolumab or Nivolumab Plus Experimental Medication BMS-986205 With or Without Bacillus Calumette-Guerin (BCG) in BCG Unresponsive Bladder Cancer That Has Not Invaded Into the Muscle Wall of the Bladder", "status": "TERMINATED", "last_update": "2023-06-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03520491", "title": "A Study to Test the Safety of Immunotherapy With Nivolumab Alone or With Ipilimumab Before Surgery for Bladder Cancer Patients Who Are Not Suitable for Chemotherapy", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-02-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03529890", "title": "Radio-Immunotherapy Before Cystectomy in Locally Advanced Urothelial Carcinoma of the Bladder", "status": "UNKNOWN", "last_update": "2022-10-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03532451", "title": "Phase Ib Feasibility Trial of Neoadjuvant Nivolumab/Lirilumab in Cisplatin-Ineligible Muscle-Invasive Bladder Cancer", "status": "COMPLETED", "last_update": "2024-09-19", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03534804", "title": "Cabozantinib Plus Pembrolizumab as First-Line Therapy for Cisplatin-Ineligible Advanced Urothelial Carcinoma", "status": "COMPLETED", "last_update": "2024-11-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03558087", "title": "Gemcitabine, Cisplatin, Plus Nivolumab in Patients With Muscle-invasive Bladder Cancer With Selective Bladder Sparing", "status": "COMPLETED", "last_update": "2024-06-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03582475", "title": "Pembrolizumab With Combination Chemotherapy in Treating Participants With Locally Advanced or Metastatic Small Cell/Neuroendocrine Cancers of Urothelium or Prostate", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-11-12", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03589339", "title": "NBTXR3 Activated by Radiotherapy for Patients With Advanced Cancers Treated With An Anti-PD-1 Therapy", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-10-24", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03606174", "title": "A Phase 2 Study of Sitravatinib in Combination With PD-(L)1 Checkpoint Inhibitor Regimens in Patients With Advanced or Metastatic Urothelial Carcinoma", "status": "TERMINATED", "last_update": "2023-08-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03621982", "title": "Study of ADCT-301 in Patients With Selected Advanced Solid Tumors", "status": "TERMINATED", "last_update": "2024-06-13", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03628716", "title": "CV301 Combined With PD-1/L1 Blockade in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer", "status": "COMPLETED", "last_update": "2022-04-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03629756", "title": "A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Malignancies", "status": "COMPLETED", "last_update": "2024-05-24", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03633110", "title": "Safety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted Vaccine", "status": "COMPLETED", "last_update": "2022-04-19", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03637803", "title": "Live Biotherapeutic Product MRx0518 and Pembrolizumab Combination Study in Solid Tumors", "status": "TERMINATED", "last_update": "2023-06-01", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03661320", "title": "A Study to Compare Chemotherapy Alone Versus Chemotherapy Plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Therapy After Surgery With Nivolumab or Nivolumab and BMS-986205 in Participants With Muscle Invasive Bladder Cancer", "status": "COMPLETED", "last_update": "2026-09-10", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03693014", "title": "A Study of Several Radiation Doses for Patients With Progression on Immunotherapy/Checkpoint Inhibitors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03711032", "title": "Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (MK-3475-676/KEYNOTE-676)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-01", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03715985", "title": "Personalized Neo-antigen Vaccine in Advanced Solid Tumors (NeoPepVac)", "status": "UNKNOWN", "last_update": "2022-01-11", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03775850", "title": "A Study of EDP1503 in Patients With Colorectal Cancer, Breast Cancer, and Checkpoint Inhibitor Relapsed Tumors", "status": "COMPLETED", "last_update": "2023-03-24", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03785925", "title": "A Single-Arm Study of Bempegaldesleukin (NKTR-214) Plus Nivolumab in Cisplatin Ineligible Patients Who Have Locally Advanced or Metastatic Urothelial Cancer", "status": "COMPLETED", "last_update": "2023-03-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03832673", "title": "Pembrolizumab-Epacadostat Combination to Treat Muscle-invasive Bladder UrotheLIAl canceR: PECULIAR Study", "status": "WITHDRAWN", "last_update": "2021-02-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03836352", "title": "Study of an Immunotherapeutic, DPX-Survivac, in Combination With Low Dose Cyclophosphamide & Pembrolizumab, in Subjects With Selected Advanced & Recurrent Solid Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2022-03-31", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03844256", "title": "A Study of Mitomycin-c/ Capecitabine ChemoRadiotherapy Combined With Nivolumab Monotherapy or Ipilumimab and Nivolumab, as Bladder Sparing Curative Treatment for Muscle Invasive Bladder Cancer: the CRIMI Study", "status": "UNKNOWN", "last_update": "2022-08-12", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03854474", "title": "Testing the Addition of Tazemetostat to the Immunotherapy Drug, Pembrolizumab (MK-3475), in Advanced Urothelial Carcinoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-31", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03872947", "title": "A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-23", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03884556", "title": "TTX-030 Single Agent and in Combination With Immunotherapy or Chemotherapy for Patients With Advanced Cancers", "status": "COMPLETED", "last_update": "2025-07-02", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03915678", "title": "Atezolizumab Combined With BDB001 AnD Immunogenic Radiotherapy in Patients With Advanced Solid Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03924856", "title": "Perioperative Pembrolizumab (MK-3475) Plus Neoadjuvant Chemotherapy Versus Perioperative Placebo Plus Neoadjuvant Chemotherapy for Cisplatin-eligible Muscle-invasive Bladder Cancer (MIBC) (MK-3475-866/KEYNOTE-866)", "status": "COMPLETED", "last_update": "2026-07-22", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03924895", "title": "Perioperative Pembrolizumab (MK-3475) Plus Cystectomy or Perioperative Pembrolizumab Plus Enfortumab Vedotin Plus Cystectomy Versus Cystectomy Alone in Participants Who Are Cisplatin-ineligible or Decline Cisplatin With Muscle-invasive Bladder Cancer (MK-3475-905/KEYNOTE-905/EV-303)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-30", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03935347", "title": "Adoptive Cell Therapy With (LN-145) in Combination With Pembrolizumab in Treating Patients With Unresectable or Metastatic Transitional Cell Cancer Who Have Failed Cisplatin-Based Chemotherapy", "status": "WITHDRAWN", "last_update": "2020-01-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03978624", "title": "Window of Opportunity Study of Pembrolizumab Alone and in Combinations in Bladder Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-10-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03980041", "title": "Study to Evaluate the Efficacy/Safety of IPI-549 in Combination With Nivolumab in Patients With Advanced Urothelial Carcinoma (MARIO-275)", "status": "COMPLETED", "last_update": "2022-11-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03993249", "title": "Nivolumab Plus Chemoradiotherapy in Patients With Muscle-invasive Bladder Cancer (MIBC) Not Undergoing Cystectomy", "status": "UNKNOWN", "last_update": "2022-03-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04099589", "title": "Neoadjuvant Treatment of Upper Urinary and Muscular Invasive Bladder Urothelial Carcinoma", "status": "UNKNOWN", "last_update": "2022-03-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04101812", "title": "Pegylated Liposomal Doxorubicin, PD-1 in Treating Muscle Invasive Bladder Cancer", "status": "UNKNOWN", "last_update": "2019-09-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04149574", "title": "A Study Comparing the Efficacy and Safety of Nivolumab in Combination With Bacillus Calmette-Guerin (BCG) Versus BCG Alone in Participants With High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC)", "status": "TERMINATED", "last_update": "2025-09-16", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04157985", "title": "Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors", "status": "COMPLETED", "last_update": "2025-12-11", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04164082", "title": "Testing the Addition of an Anti-cancer Drug, Pembrolizumab, to the Usual Intravesical Chemotherapy Treatment (Gemcitabine) for the Treatment of BCG-Unresponsive Non-muscle Invasive Bladder Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04165317", "title": "A Study of Sasanlimab in People With Non-muscle Invasive Bladder Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-01-22", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04180371", "title": "Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-11-17", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04200963", "title": "A Phase 1a/b Study of IK-175 as a Single Agent and in Combination With Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumors and Urothelial Carcinoma", "status": "COMPLETED", "last_update": "2024-03-15", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04209114", "title": "A Study of Nivolumab Plus Bempegaldesleukin (Bempeg/NKTR-214) vs Nivolumab Alone vs Standard of Care in Participants With Bladder Cancer That May Have Invaded The Muscle Wall of the Bladder and Who Cannot Get Cisplatin, A Type of Medicine Given To Treat Bladder Cancer", "status": "COMPLETED", "last_update": "2024-06-27", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04234113", "title": "Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors", "status": "TERMINATED", "last_update": "2026-03-27", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04241185", "title": "Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Muscle-invasive Bladder Cancer (MIBC) (MK-3475-992/KEYNOTE-992)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-01", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04260802", "title": "A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers", "status": "TERMINATED", "last_update": "2026-01-12", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04306900", "title": "TTX-030 in Combination With Immunotherapy and/or Chemotherapy in Subjects With Advanced Cancers", "status": "COMPLETED", "last_update": "2025-07-29", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04311710", "title": "A Study Evaluating the Drug Levels of Iplimumab Given Under the Skin Alone and in Combination With Nivolumab in Multiple Tumor Types", "status": "TERMINATED", "last_update": "2023-02-24", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04383743", "title": "Pembrolizumab and Combination Chemotherapy Before Surgery for the Treatment of Muscle-Invasive Bladder Cancer", "status": "COMPLETED", "last_update": "2025-09-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04383938", "title": "Phase 1/2 Study of APR-246 in Combination With Pembrolizumab in Subjects With Solid Tumor Malignancies", "status": "COMPLETED", "last_update": "2025-05-13", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04387461", "title": "Study of CG0070 Given in Combination With Pembrolizumab, in Non-Muscle Invasive Bladder Cancer, Unresponsive to Bacillus Calmette-Guerin", "status": "COMPLETED", "last_update": "2024-09-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04430036", "title": "AGEN1884 Plus AGEN2034 Combined With Cisplatin-Gemcitabine for Muscle-Invasive Bladder Cancer", "status": "TERMINATED", "last_update": "2024-04-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04432857", "title": "AN0025 and Pembrolizumab Combination in Advanced Solid Tumors", "status": "UNKNOWN", "last_update": "2024-06-27", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04485013", "title": "TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-11", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04506554", "title": "A Study of Risk Enabled Therapy After Neoadjuvant Immunochemotherapy for Bladder Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-07-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04561362", "title": "Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced Malignancies", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-11-14", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04579224", "title": "Comparing the New Anti-cancer Drug Eribulin With Chemotherapy Against the Usual Chemotherapy Alone in Metastatic Urothelial Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-04", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04580485", "title": "INCB106385 Alone or in Combination With Immunotherapy in Advanced Solid Tumors", "status": "COMPLETED", "last_update": "2025-07-11", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04610671", "title": "Study of CG0070 Combined With Nivolumab in Cisplatin Ineligible Patients With MIBC", "status": "COMPLETED", "last_update": "2026-02-27", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04637594", "title": "Trying to Find the Correct Length of Treatment With Immune Checkpoint Therapy", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-03-20", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04660929", "title": "CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors", "status": "UNKNOWN", "last_update": "2024-12-18", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04690699", "title": "LUMINOS-103: A Basket Trial of Safety & Efficacy of Lerapolturev With or Without Checkpoint Inhibitors", "status": "TERMINATED", "last_update": "2024-10-24", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04700124", "title": "Perioperative Enfortumab Vedotin (EV) Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Chemotherapy for Cisplatin-Eligible Muscle Invasive Bladder Cancer (MIBC) (MK-3475-B15/ KEYNOTE-B15 / EV-304)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-16", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04701918", "title": "Cryoablation With Pembrolizumab Or Avelumab In Urothelial Carcinoma", "status": "COMPLETED", "last_update": "2026-01-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04779151", "title": "Basket Trial Exploring the Efficacy and Safety of the Combination of Niraparib and Dostarlimab", "status": "TERMINATED", "last_update": "2025-12-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04848519", "title": "Immune Checkpoint Inhibitors With or Without Propranolol Hydrochloride In Patients With Urothelial Carcinoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-02-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04863885", "title": "Combination of Ipi/Nivo Plus Sacituzumab Govitecan in Metastatic Cisplatin Ineligible Urothelial Carcinoma Patients", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-12-17", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04876313", "title": "An Open Label, Single-arm, Phase 2 Study of Neoadjuvant Nivolumab and Nab-paclitaxel Before Radical Cystectomy for Patients With Muscle-invasive Bladder Cancer (NURE-Combo)", "status": "UNKNOWN", "last_update": "2022-04-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04902040", "title": "Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies", "status": "TERMINATED", "last_update": "2026-04-30", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04909775", "title": "Chemotherapy Combined With Tislelizumab as Bladder Sparing Option for Patients With Muscle Invasive Bladder Cancer", "status": "UNKNOWN", "last_update": "2021-06-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04922047", "title": "Safety and Efficacy Study of Tislelizumab in Combination With BCG in HR-NMIBC Patients (TACBIN-01)", "status": "UNKNOWN", "last_update": "2021-06-11", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04936230", "title": "Immunotherapy With or Without Radiation Therapy for Metastatic Urothelial Cancer", "status": "TERMINATED", "last_update": "2025-08-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04940299", "title": "Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-03-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04953104", "title": "ARID1A and/or KDM6A Mutation and CXCL13 Expression", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-04-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04960709", "title": "Treatment Combination of Durvalumab, Tremelimumab and Enfortumab Vedotin or Durvalumab and Enfortumab Vedotin in Patients With Muscle Invasive Bladder Cancer Ineligible to Cisplatin or Who Refuse Cisplatin", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-04", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05007106", "title": "MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005)", "status": "COMPLETED", "last_update": "2025-08-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05061537", "title": "Study of PF-07263689 in Participants With Selected Advanced Solid Tumors", "status": "TERMINATED", "last_update": "2024-04-12", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05077709", "title": "IO102-IO103 in Combination With Pembrolizumab as First-line Treatment for Patients With Metastatic NSCLC, SCCHN, or mUBC", "status": "COMPLETED", "last_update": "2026-04-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05200988", "title": "Checkpoint Inhibition and Chemoradiotherapy as Bladder Sparing Treatment in UC", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2024-03-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05215574", "title": "Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2024-10-10", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05241340", "title": "Neoadjuvant Sasanlimab With Radiation as an in Situ Vaccine for Cisplatin-ineligible Muscle Invasive Bladder Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-10-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05259397", "title": "PF-07225570 Alone or in Combination With an Anti-PD-1 Antibody in Recurrent Non-muscle Invasive Bladder Cancer (NMIBC)", "status": "WITHDRAWN", "last_update": "2023-03-08", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05311618", "title": "Study of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors", "status": "UNKNOWN", "last_update": "2024-04-01", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05406713", "title": "Pembrolizumab in Muscle-invasive Bladder Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-04-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05429866", "title": "Immunological Variables Associated to ICI Toxicity in Cancer Patients", "status": "UNKNOWN", "last_update": "2023-03-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05496192", "title": "A Study of Nivolumab Intravenous (IV) to Subcutaneous (SC) Switch in Adjuvant Melanoma and Bladder Cancer", "status": "WITHDRAWN", "last_update": "2023-04-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05531123", "title": "Risk-stratification Based Bladder-sparing Modalities for Muscle-invasive Bladder Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05535218", "title": "Pembrolizumab-Sacituzumab Govitecan Combination to Treat High-risk, Localized Bladder Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-04-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05564897", "title": "Oncolytic Adenovirus Combined With PD-1 Inhibitor in Patients With Non-muscle-invasive Bladder Cancer", "status": "UNKNOWN", "last_update": "2022-10-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05687721", "title": "Copanlisib and Avelumab as a Maintenance Therapy for Advanced Bladder Cancer", "status": "WITHDRAWN", "last_update": "2025-06-15", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05788484", "title": "A Study of CDX-585 in Patients With Advanced Malignancies", "status": "COMPLETED", "last_update": "2025-06-15", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05829057", "title": "The IIT Study of Evaluation of P-IL-2 Single Agent and With Anti-PD-1", "status": "UNKNOWN", "last_update": "2024-02-13", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05843448", "title": "IDO and PD-L1 Peptide Based Immune-Modulatory Therapeutic (IO102-IO103) in Combination With Pembrolizumab for BCG-Unresponsive or Intolerant, Non-Muscle Invasive Bladder Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-16", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05858736", "title": "Safety, PK and Efficacy of AI-061 in Advanced Solid Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-04-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05911295", "title": "Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-22", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05975307", "title": "Treating Muscle-invasive Bladder Cancer With A Non-surgical Method Consisting of Anti-PD-1 Therapy and Chemoradiation", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-12-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05979740", "title": "RC48 Combined With Toripalimab and Radiotherapy for Bladder Sparing Treatment in MIBC", "status": "UNKNOWN", "last_update": "2023-08-31", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06050954", "title": "A Pilot Study of Circulating Tumor DNA Adaptive Risk Maintenance Approach for Bladder Cancer (CARMA)", "status": "WITHDRAWN", "last_update": "2023-11-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06059547", "title": "Neoadjuvant Immunotherapy Combined With the Anti-GDF-15 Antibody Visugromab to Treat Muscle Invasive Bladder Cancer", "status": "COMPLETED", "last_update": "2026-08-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06204614", "title": "Drug Screening Using IMD in Bladder Cancer", "status": "ENROLLING_BY_INVITATION", "last_update": "2026-05-18", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06225596", "title": "Study BT8009-230 in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06237920", "title": "Stage II-IIIa Urothelial Cancer Randomizing Pre-operative Nivolumab With or Without Relatlimab", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06305767", "title": "A Clinical Study of Intismeran Autogene (V940) Treatment and Pembrolizumab in People With Bladder Cancer (V940-005/INTerpath-005)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-01-13", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06448364", "title": "A Study in Advanced/Metastatic Solid Tumors With the Study Medicine (PF-07329640) When Given Alone or In Combination", "status": "TERMINATED", "last_update": "2024-11-06", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06580938", "title": "A Study to Learn About PF-07921585 Alone or With Other Anti-cancer Medicines in People With Cancer", "status": "TERMINATED", "last_update": "2026-03-23", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06957561", "title": "Disitamab Vedotin Combined With Ivonescimab in Cisplatin-Ineligible Muscle-Invasive Bladder Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2025-05-04", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07142200", "title": "A Clinical Study Evaluating the Efficacy and Safety of Disitamab Vedotin Combined With PD-1 Inhibitor and Radiotherapy as Bladder-preserving Therapy in Patients With Localized HER2-high Expressing Muscle-invasive Bladder Urothelial Carcinoma Following Maximal Transurethral Resection", "status": "NOT_YET_RECRUITING", "last_update": "2025-08-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07189793", "title": "Toripalimab \u00b1 Sequential Intravesical Gemcitabine-Mitomycin C for BCG-Unresponsive/-Intolerant High-Risk NMIBC: Open-Label Randomized Phase 2 Study", "status": "NOT_YET_RECRUITING", "last_update": "2026-09-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07218003", "title": "A Phase 1/1b of RNDO-564 Single Agent or in Combination With Pembrolizumab in Bladder Cancer and Other Solid Tumors Associated With Nectin-4", "status": "ENROLLING_BY_INVITATION", "last_update": "2026-06-11", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07346053", "title": "The Impact of Time-of-day Administration of EV/P on Objective Response Rate in Adults With Advanced Bladder Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2026-01-16", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07353294", "title": "Propranolol With Tislelizumab Plus GC in Neoadjuvant Bladder UC", "status": "ENROLLING_BY_INVITATION", "last_update": "2026-04-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07474064", "title": "Probiotics Combined With Targeted Therapy Plus Immunotherapy in Bladder-Preserving Setting for Patients With MIBC", "status": "NOT_YET_RECRUITING", "last_update": "2026-03-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07608224", "title": "HOPE-07-MIBC: Disitamab Vedotin Plus Immunotherapy vs Chemoimmunotherapy in Resectable HER2-Expressing MIBC", "status": "NOT_YET_RECRUITING", "last_update": "2026-05-27", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07625527", "title": "Is Prolonged Systemic Immunotherapy Necessary After Achieving Tumor-free Status in Patients With Extensive Transurethrally Unresectable Very-high-risk NMIBC?", "status": "NOT_YET_RECRUITING", "last_update": "2026-06-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07643519", "title": "Neoadjuvant Enfortumab Vedotin Plus Pembrolizumab in Muscle-Invasive Bladder Cancer and Upper Tract Urothelial Carcinoma", "status": "NOT_YET_RECRUITING", "last_update": "2026-06-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07663747", "title": "Enfortumab Vedotin + Pembrolizumab Induction to Spare the Bladder in MIBC", "status": "NOT_YET_RECRUITING", "last_update": "2026-06-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07667335", "title": "Enfortumab Vedotin, Pembrolizumab and Quemliclustat for the Treatment of Unresectable Locally Advanced and Metastatic Urothelial Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2026-09-04", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" } ], "cell_therapy": { "n": 5, "n_observational": 0, "n_active": 1, "n_withdrawn": 2, "trials": [ { "nct": "NCT07410676", "title": "EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 \u00b1 Pembrolizumab in Advanced Solid Tumors", "status": "RECRUITING", "last_update": "2026-02-18", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02863913", "title": "PD-1 Knockout Engineered T Cells for Muscle-invasive Bladder Cancer", "status": "WITHDRAWN", "last_update": "2019-03-06", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03785925", "title": "A Single-Arm Study of Bempegaldesleukin (NKTR-214) Plus Nivolumab in Cisplatin Ineligible Patients Who Have Locally Advanced or Metastatic Urothelial Cancer", "status": "COMPLETED", "last_update": "2023-03-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03935347", "title": "Adoptive Cell Therapy With (LN-145) in Combination With Pembrolizumab in Treating Patients With Unresectable or Metastatic Transitional Cell Cancer Who Have Failed Cisplatin-Based Chemotherapy", "status": "WITHDRAWN", "last_update": "2020-01-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04209114", "title": "A Study of Nivolumab Plus Bempegaldesleukin (Bempeg/NKTR-214) vs Nivolumab Alone vs Standard of Care in Participants With Bladder Cancer That May Have Invaded The Muscle Wall of the Bladder and Who Cannot Get Cisplatin, A Type of Medicine Given To Treat Bladder Cancer", "status": "COMPLETED", "last_update": "2024-06-27", "phase": "PHASE3", "study_type": "INTERVENTIONAL" } ] }, "synonyms_searched": [ "PD-1", "pembrolizumab", "nivolumab" ] }, "HER2": { "n": 70, "n_observational": 7, "n_active": 39, "n_withdrawn": 2, "trials": [ { "nct": "NCT03740256", "title": "Binary Oncolytic Adenovirus in Combination With HER2-Specific Autologous CAR VST, Advanced HER2 Positive Solid Tumors", "status": "RECRUITING", "last_update": "2026-02-06", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04389632", "title": "A Study of Sigvotatug Vedotin in Advanced Solid Tumors", "status": "RECRUITING", "last_update": "2026-07-06", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04879329", "title": "A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2", "status": "RECRUITING", "last_update": "2026-07-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05614739", "title": "FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3", "status": "RECRUITING", "last_update": "2026-08-20", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05786716", "title": "DETERMINE Trial Treatment Arm 04: Trastuzumab in Combination With Pertuzumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With HER2 Amplification or Activating Mutations", "status": "RECRUITING", "last_update": "2025-12-02", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05943379", "title": "RC48-ADC in Combination With Gemcitabine in High Risk NMIBC Subjects", "status": "RECRUITING", "last_update": "2023-07-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06253871", "title": "A Phase 1/1b Study of IAM1363 in HER2 Cancers", "status": "RECRUITING", "last_update": "2026-09-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06378242", "title": "To Evaluate the Safety, Efficacy, and Pharmacokinetics of Intravesical Instiliations of Disitamab Vedotin in Patients With High-risk Non-muscular Invasive Bladder Cancer (NMIBC) That Express HER2", "status": "RECRUITING", "last_update": "2024-07-11", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06548529", "title": "HER2 Expression of HER2 Affibody-based PET/CT to Predict Response in Bladder Cancer Patients Treated With ADC", "status": "RECRUITING", "last_update": "2024-08-23", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06760819", "title": "A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)", "status": "RECRUITING", "last_update": "2026-09-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07207824", "title": "DV+BCG in HER2-Expressing, BCG-Na\u00efve High-Risk NMIBC", "status": "RECRUITING", "last_update": "2026-07-21", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07296705", "title": "Neoadjuvant Zanidatamab + Tislelizumab + Chemotherapy for Selective Bladder Preservation in HER2-Positive MIBC", "status": "RECRUITING", "last_update": "2025-12-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07492628", "title": "Dual-Target Nectin-4/HER2 CAR-NK Cells in Advanced Urothelial Carcinoma", "status": "RECRUITING", "last_update": "2026-03-25", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07646145", "title": "Disitamab Vedotin Plus Intravesical Mitomycin C in HER2-Expressing Intermediate- to High-Risk Non-Muscle-Invasive Bladder Cancer", "status": "RECRUITING", "last_update": "2026-06-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07660055", "title": "Study of [177Lu]Lu-DWJ155 and [68Ga]Ga-DWJ155 in Patients With Solid Tumors", "status": "RECRUITING", "last_update": "2026-08-27", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07717242", "title": "Sun Yat-Sen Treatment Strategy for Enhancing Response in Muscle-invasive Bladder Cancer", "status": "RECRUITING", "last_update": "2026-07-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00004074", "title": "Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu", "status": "COMPLETED", "last_update": "2013-02-28", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00004856", "title": "Trastuzumab in Treating Patients With Previously Treated, Locally Advanced, or Metastatic Cancer of the Urothelium", "status": "TERMINATED", "last_update": "2013-05-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00005831", "title": "Trastuzumab and Combination Chemotherapy in Treating Patients With Locally Recurrent or Metastatic Urinary Tract Cancer", "status": "COMPLETED", "last_update": "2013-01-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00005842", "title": "Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic Cancer", "status": "COMPLETED", "last_update": "2013-02-11", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00238420", "title": "Paclitaxel and Radiation Therapy With or Without Trastuzumab in Treating Patients Who Have Undergone Surgery for Bladder Cancer", "status": "COMPLETED", "last_update": "2022-07-19", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00447226", "title": "Randomized Discontinuation Study of Lapatinib Versus Placebo in Subjects With Documented Tumor Progression After Chemotherapy, or Where no Approved Therapy Exists", "status": "TERMINATED", "last_update": "2012-06-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00949455", "title": "A Double Blind Randomised Study of Lapatinib and Placebo in Metastatic TCC of the Urothelium", "status": "UNKNOWN", "last_update": "2015-04-15", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01353222", "title": "DN24-02 as Adjuvant Therapy in Subjects With High Risk HER2+ Urothelial Carcinoma", "status": "TERMINATED", "last_update": "2017-05-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01828736", "title": "Efficacy of Combination of Trastuzumab to Gemcitabine - Platinum Advanced or Metastatic Urothelial Carcinoma", "status": "COMPLETED", "last_update": "2017-02-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02091141", "title": "My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors", "status": "COMPLETED", "last_update": "2024-07-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02465060", "title": "Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02675829", "title": "Trial of Ado-Trastuzumab Emtansine for Patients With HER2 Amplified or Mutant Cancers", "status": "COMPLETED", "last_update": "2026-09-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02999672", "title": "A Study to Determine Best Tumor Response With Trastuzumab Emtansine in Human Epidermal Growth Factor Receptor 2 (HER2) Overexpressing Solid Tumors", "status": "COMPLETED", "last_update": "2019-08-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03125200", "title": "Study of ADCT-502 in Patients With Advanced Solid Tumors Withhuman Epidermal Growth Factor Receptor-2 (HER2) Expression", "status": "TERMINATED", "last_update": "2021-02-01", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03330561", "title": "PRS-343 in HER2-Positive Solid Tumors", "status": "COMPLETED", "last_update": "2024-04-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03602079", "title": "Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene", "status": "COMPLETED", "last_update": "2023-08-03", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03650348", "title": "PRS-343 in Combination With Atezolizumab in HER2-Positive Solid Tumors", "status": "COMPLETED", "last_update": "2024-04-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03929666", "title": "A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer", "status": "COMPLETED", "last_update": "2025-09-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04209465", "title": "A Study of BDTX-189, an Orally Available Allosteric ErbB Inhibitor, in Patients With Advanced Solid Tumors.", "status": "TERMINATED", "last_update": "2025-04-17", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04319757", "title": "ACE1702 in Subjects With Advanced or Metastatic HER2-expressing Solid Tumors", "status": "COMPLETED", "last_update": "2024-12-05", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04464967", "title": "Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR Cancers", "status": "WITHDRAWN", "last_update": "2021-05-12", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04482309", "title": "A Phase 2 Study of T-DXd in Patients With Selected HER2 Expressing Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04485013", "title": "TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-11", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04602117", "title": "ISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer", "status": "WITHDRAWN", "last_update": "2023-11-18", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04644068", "title": "Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-19", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04660929", "title": "CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors", "status": "UNKNOWN", "last_update": "2024-12-18", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05016973", "title": "A Clinical Study of RC48-ADC Combined With Triplizumab For Treatment of Myometrial Invasive Bladder Cancer", "status": "UNKNOWN", "last_update": "2021-08-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05356351", "title": "An Open-label, Single-arm, Multicenter Phase II Clinical Study\uff1a Evaluating RC48-ADC Combined With Triplizumab in the Neoadjuvant Treatment of Her2-positive Muscle-invasive Bladder Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2022-05-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05488353", "title": "A Clinical Study of Disitamab Vedotin for Injection Combined With Penpulimab Injection in Neoadjuvant Therapy for Patients With HER2-expressing Cisplatin-intolerant cT2-T4aNxM0 Bladder Urothelial Carcinoma", "status": "UNKNOWN", "last_update": "2022-08-04", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05495724", "title": "Disitamab Vedotin Combined With Tislelizumab for Her2 Overexpressing High-Risk Non-Muscle-Invasive Urothelial Bladder Carcinoma Which is Not Completely Resectable", "status": "UNKNOWN", "last_update": "2022-08-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05723991", "title": "Study of Disitamab Vedotin Combined With Gemcitabine in Neoadjuvant Treatment of Urothelial Carcinoma", "status": "UNKNOWN", "last_update": "2023-02-13", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05911295", "title": "Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-22", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05912205", "title": "Disitamab Vedotin Combined With Radiotherapy for Bladder Preservation", "status": "UNKNOWN", "last_update": "2023-06-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05957757", "title": "RC48 Combined With Tislelizumab for Bladder Sparing Treatment in NMIBC With BCG Treatment Failure and HER2 Expression", "status": "UNKNOWN", "last_update": "2023-08-31", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05979740", "title": "RC48 Combined With Toripalimab and Radiotherapy for Bladder Sparing Treatment in MIBC", "status": "UNKNOWN", "last_update": "2023-08-31", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05996952", "title": "RC48-ADC in Adjuvant/Salvage Treatment of HER2 Positive Non-muscle-invasive Bladder Cancer", "status": "UNKNOWN", "last_update": "2023-08-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06074484", "title": "A Study of RC48-ADC Combined With AK104 For Perioperative Treatment of Muscle-Invasive Bladder Cancer", "status": "UNKNOWN", "last_update": "2023-10-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06187506", "title": "Disitamab Vedotin Combined With BCG Therapy in HER2-expressing High-risk Non-muscle Invasive Bladder Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06257264", "title": "A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-18", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06630871", "title": "A Clinical Trial Evaluating the Efficacy and Safety of Disitamab Vedotin Plus Tislelizumab Combined with Re-TURBT in the Treatment of HER-2-high Expression(2+-3+) Non-muscle Invasive Bladder Cancer At High-risk and Very High-risk.", "status": "NOT_YET_RECRUITING", "last_update": "2024-10-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06714617", "title": "Evaluate BL-M17D1 in Patients w/HER2-Expressing/Mutant Advanced or Metastatic Solid Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-11-04", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06957561", "title": "Disitamab Vedotin Combined With Ivonescimab in Cisplatin-Ineligible Muscle-Invasive Bladder Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2025-05-04", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07100184", "title": "RC48 in Combination With Radiotherapy for HER2-Expressing NMIBC Patients", "status": "NOT_YET_RECRUITING", "last_update": "2025-08-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07142200", "title": "A Clinical Study Evaluating the Efficacy and Safety of Disitamab Vedotin Combined With PD-1 Inhibitor and Radiotherapy as Bladder-preserving Therapy in Patients With Localized HER2-high Expressing Muscle-invasive Bladder Urothelial Carcinoma Following Maximal Transurethral Resection", "status": "NOT_YET_RECRUITING", "last_update": "2025-08-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07151560", "title": "Efficacy and Safety of Two Bladder-preserving Treatment Durations With Disitamab Vedotin Plus Toripalimab Combination in Her2-expressing Muscle-invasive Bladder Cancer: A Phase II, Open-Label, Randomized Clinical Trial", "status": "NOT_YET_RECRUITING", "last_update": "2025-09-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07279597", "title": "A Phase II Study of Toripalimab Plus RC48-ADC With Radiotherapy for Bladder Preservation in HER2-Positive Muscle-Invasive Bladder Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2025-12-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07474064", "title": "Probiotics Combined With Targeted Therapy Plus Immunotherapy in Bladder-Preserving Setting for Patients With MIBC", "status": "NOT_YET_RECRUITING", "last_update": "2026-03-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07608224", "title": "HOPE-07-MIBC: Disitamab Vedotin Plus Immunotherapy vs Chemoimmunotherapy in Resectable HER2-Expressing MIBC", "status": "NOT_YET_RECRUITING", "last_update": "2026-05-27", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07624201", "title": "Trastuzumab Rezetecan and Adebrelimab as Neoadjuvant Therapy for HER2-Positive Muscle-Invasive Bladder Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2026-06-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07639983", "title": "Multi-Omics-Based Phase \u2161 Trial of Trastuzumab Rezetecan Plus Camrelizumab for Perioperative Therapy in HER2-Positive Muscle-Invasive Urothelial Carcinoma", "status": "NOT_YET_RECRUITING", "last_update": "2026-06-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07662863", "title": "Sacituzumab Tirumotecan vs MMAE-ADCs in Advanced Urothelial Carcinoma (FUSCC-SPARE-UC-01)", "status": "NOT_YET_RECRUITING", "last_update": "2026-06-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07690878", "title": "PTC-guided Neoadjuvant Therapy For Muscle-invasive Bladder Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2026-07-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07756008", "title": "Bladder-Sparing Treatment With Disitamab Vedotin and Toripalimab With or Without Pelvic Lymph Node Dissection in Bladder Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2026-08-10", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07783815", "title": "A Study to Evaluate the Efficacy and Safety of Intravesical Instillation of Disitamab Vedotin Combined With Toripalimab in Patients With HER2-Positive High-Risk Non-Muscle Invasive Bladder Cancer Who Are BCG-Na\u00efve or Have BCG Failure", "status": "NOT_YET_RECRUITING", "last_update": "2026-08-25", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ], "cell_therapy": { "n": 1, "n_observational": 0, "n_active": 1, "n_withdrawn": 0, "trials": [ { "nct": "NCT07492628", "title": "Dual-Target Nectin-4/HER2 CAR-NK Cells in Advanced Urothelial Carcinoma", "status": "RECRUITING", "last_update": "2026-03-25", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ] }, "synonyms_searched": [ "HER2", "ERBB2", "disitamab", "trastuzumab" ] }, "FGFR3": { "n": 25, "n_observational": 5, "n_active": 13, "n_withdrawn": 2, "trials": [ { "nct": "NCT05614739", "title": "FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3", "status": "RECRUITING", "last_update": "2026-08-20", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06319820", "title": "A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer", "status": "RECRUITING", "last_update": "2026-08-28", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06511648", "title": "Erdafitinib Monotherapy or in Combination With Cetrelimab in Muscle-invasive Bladder Cancer Patients With Fibroblast Growth Factor Receptor (FGFR ) Gene Alterations", "status": "RECRUITING", "last_update": "2025-12-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06919965", "title": "A Study to Evaluate TAR-210 Versus Intravesical Chemotherapy Treatment in Participants With High Risk Non-Muscle-Invasive Bladder Cancer", "status": "RECRUITING", "last_update": "2026-08-28", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06995677", "title": "Efficacy and Safety of TYRA-300 in Participants With FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer", "status": "RECRUITING", "last_update": "2026-09-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07218380", "title": "A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract", "status": "RECRUITING", "last_update": "2026-08-21", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01732107", "title": "Dovitinib in BCG Refractory Urothelial Carcinoma With FGFR3 Mutations or Over-expression", "status": "TERMINATED", "last_update": "2022-07-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02278978", "title": "BIBF1120 in Patients With Advanced FGFR3 Mutated,Overexpressed,or Wild Type Urothelial Carcinoma", "status": "UNKNOWN", "last_update": "2015-05-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02401542", "title": "Dose Escalation, Expansion Study of Vofatamab (B-701) in Treatment of Locally Advanced or Metastatic Urothelial Cell Carcinoma", "status": "TERMINATED", "last_update": "2020-03-09", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02465060", "title": "Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02529553", "title": "A Study of LY3076226 in Participants With Advanced or Metastatic Cancer", "status": "COMPLETED", "last_update": "2020-04-17", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02925533", "title": "Ph 1B B-701 in Combination With Pembrolizumab in Metastatic Transitional Cell Carcinoma of the Urothelial Tract", "status": "TERMINATED", "last_update": "2017-06-27", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03123055", "title": "A Study of B-701 in Combination With Pembrolizumab in Treatment of Locally Advanced or Metastatic Urothelial Cell Carcinoma", "status": "TERMINATED", "last_update": "2020-03-18", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04040725", "title": "Rogaratinib for BCG Refractory High Risk Non-Muscle Invasive Bladder Cancer With FGFR1/2 Overexpression", "status": "WITHDRAWN", "last_update": "2019-12-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04172675", "title": "A Study of Erdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gu\u00e9rin (BCG) and Recurred With High Risk Non-Muscle-Invasive Bladder Cancer (NMIBC)", "status": "COMPLETED", "last_update": "2026-02-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04197986", "title": "Oral Infigratinib for the Adjuvant Treatment of Subjects With Invasive Urothelial Carcinoma With Susceptible FGFR3 Genetic Alterations", "status": "TERMINATED", "last_update": "2024-03-13", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04917809", "title": "A Study of Oral Erdafitinib in People With Recurrent Non-Invasive Bladder Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04963153", "title": "Testing Combination Erdafitinib and Enfortumab Vedotin in Metastatic Bladder Cancer After Treatment With Chemotherapy and Immunotherapy", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-31", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05151341", "title": "Study of Combined VisioCyt Test and FGFR3 Mutations on a Urinary Sample to Diagnose Bladder Tumors", "status": "COMPLETED", "last_update": "2025-07-24", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05316155", "title": "Study of Erdafitinib Intravesical Delivery System for Localized Bladder Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-28", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05363605", "title": "A Study of [225Ac]-FPI-1966 in Participants With Advanced Solid Tumours", "status": "TERMINATED", "last_update": "2023-12-19", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05544552", "title": "Safety and Preliminary Anti-Tumor Activity of TYRA-300 in Advanced Urothelial Carcinoma and Other Solid Tumors With FGFR3 Gene Alterations", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-01-12", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05564416", "title": "Testing Anti-Cancer Drugs Erdafitinib With or Without Atezolizumab in Patients With Localized Bladder Cancer Not Able to Receive Cisplatin Chemotherapy, NERA Trial", "status": "WITHDRAWN", "last_update": "2025-10-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05567185", "title": "A Study of Erdafitinib Intravesical Delivery System in Japanese Participants With Bladder Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-28", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06204614", "title": "Drug Screening Using IMD in Bladder Cancer", "status": "ENROLLING_BY_INVITATION", "last_update": "2026-05-18", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" } ], "cell_therapy": { "n": 0, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [] }, "synonyms_searched": [ "FGFR3", "erdafitinib", "Balversa" ] } }, "by_drug": { "ADEBRELIMAB": { "n": 3, "n_observational": 0, "n_active": 3, "n_withdrawn": 0, "trials": [ { "nct": "NCT06091124", "title": "Neoadjuvant Adebrelimab Plus Etoposide and Cisplatin in Neuroendocrine Bladder Carcinoma", "status": "RECRUITING", "last_update": "2025-12-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06879145", "title": "Clinical Study on the Treatment of MIBC Patients With SHR-A2102 Injection Combined With Adebrelimab (SHR-1316)", "status": "RECRUITING", "last_update": "2026-07-13", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07624201", "title": "Trastuzumab Rezetecan and Adebrelimab as Neoadjuvant Therapy for HER2-Positive Muscle-Invasive Bladder Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2026-06-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "AFATINIB": { "n": 3, "n_observational": 0, "n_active": 1, "n_withdrawn": 0, "trials": [ { "nct": "NCT02122172", "title": "Afatinib in Advanced Refractory Urothelial Cancer", "status": "TERMINATED", "last_update": "2025-04-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02465060", "title": "Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02780687", "title": "Afatinib Monotherapy in Patients With ERBB-deregulated Metastatic Urothelial Tract Carcinoma After Failure of Platinum Based Chemotherapy", "status": "COMPLETED", "last_update": "2020-11-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "AFATINIB DIMALEATE": { "n": 3, "n_observational": 0, "n_active": 1, "n_withdrawn": 0, "trials": [ { "nct": "NCT02122172", "title": "Afatinib in Advanced Refractory Urothelial Cancer", "status": "TERMINATED", "last_update": "2025-04-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02465060", "title": "Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02780687", "title": "Afatinib Monotherapy in Patients With ERBB-deregulated Metastatic Urothelial Tract Carcinoma After Failure of Platinum Based Chemotherapy", "status": "COMPLETED", "last_update": "2020-11-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "ATEZOLIZUMAB": { "n": 52, "n_observational": 0, "n_active": 21, "n_withdrawn": 2, "trials": [ { "nct": "NCT05000294", "title": "Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types", "status": "RECRUITING", "last_update": "2026-07-13", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05312671", "title": "Atezolizumab Plus Etoposide and Platinum in Small Cell Bladder Cancer", "status": "RECRUITING", "last_update": "2026-06-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05944237", "title": "HTL0039732 in Participants With Advanced Solid Tumours", "status": "RECRUITING", "last_update": "2025-06-08", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06161532", "title": "Sacituzumab Govitecan With or Without Atezolizumab Immunotherapy in Rare Genitourinary Tumors (SMART) Such as High Grade Neuroendocrine Carcinomas, Adenocarcinoma, and Squamous Cell Bladder/Urinary Tract Cancer, Renal Medullary Carcinoma and Penile C...", "status": "RECRUITING", "last_update": "2026-08-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06444815", "title": "A Study of VET3-TGI in Patients With Solid Tumors", "status": "RECRUITING", "last_update": "2026-04-07", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02091141", "title": "My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors", "status": "COMPLETED", "last_update": "2024-07-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02108652", "title": "A Study of Atezolizumab in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer (Cohort 2)", "status": "COMPLETED", "last_update": "2024-03-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02302807", "title": "A Study of Atezolizumab Compared With Chemotherapy in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer [IMvigor211]", "status": "COMPLETED", "last_update": "2019-08-01", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02451423", "title": "Neoadjuvant Atezolizumab in Localized Bladder Cancer", "status": "COMPLETED", "last_update": "2024-05-31", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02543645", "title": "A Study of Varlilumab and Atezolizumab in Patients With Advanced Cancer", "status": "TERMINATED", "last_update": "2018-04-30", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02662309", "title": "Preoperative MPDL3280A in Transitional Cell Carcinoma of the Bladder", "status": "COMPLETED", "last_update": "2025-03-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02792192", "title": "Safety and Pharmacology Study of Atezolizumab Alone and in Combination With Bacille Calmette-Gu\u00e9rin (BCG) in High-Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) Participants", "status": "TERMINATED", "last_update": "2021-10-28", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02807636", "title": "Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma", "status": "COMPLETED", "last_update": "2025-02-24", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02844816", "title": "Atezolizumab in Treating Patients With Recurrent BCG-Unresponsive Non-muscle Invasive Bladder Cancer", "status": "COMPLETED", "last_update": "2025-05-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02951767", "title": "A Study of Atezolizumab in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer (Cohort 1)", "status": "COMPLETED", "last_update": "2024-03-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02989584", "title": "A Phase II Study of Atezolizumab in Combination With Cisplatin + Gemcitabine Before Surgery to Remove the Bladder Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-01-07", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03007719", "title": "Functional Imaging of T-Cell Activation With [18F]F-AraG in Urothelial Carcinoma Patients Receiving Neoadjuvant Therapy or Patients With Cancer Receiving Standard of Care Anti-PD-1/L1", "status": "TERMINATED", "last_update": "2020-01-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03093922", "title": "A Study of Two Dosing Schedules of Atezolizumab in Combination With Gemcitabine and Cisplatin as First-Line Treatment for Metastatic Bladder Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-04-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03170960", "title": "Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-08-17", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03179943", "title": "Atezolizumab + Guadecitabine in Patients With Checkpoint Inhibitor Refractory or Resistant Urothelial Carcinoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2021-11-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03237780", "title": "Atezolizumab With or Without Eribulin Mesylate in Treating Patients With Recurrent Locally Advanced or Metastatic Urothelial Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-31", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03289962", "title": "A Study of Autogene Cevumeran (RO7198457) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors", "status": "COMPLETED", "last_update": "2026-06-08", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03359239", "title": "Atezolizumab Given in Combination With a Personalized Vaccine in Patients With Urothelial Cancer", "status": "COMPLETED", "last_update": "2023-05-16", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03473756", "title": "Phase 1b/2 Study of Rogaratinib (BAY1163877) in Combination With Atezolizumab in Urothelial Carcinoma", "status": "COMPLETED", "last_update": "2025-04-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03513952", "title": "Atezolizumab and CYT107 in Treating Participants With Locally Advanced, Inoperable, or Metastatic Urothelial Carcinoma", "status": "COMPLETED", "last_update": "2024-07-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03577132", "title": "The Efficacy of Neoadjuvant Atezolizumab Treatment in Patients With Advanced Urothelial Bladder Cancer", "status": "UNKNOWN", "last_update": "2018-07-31", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03620435", "title": "Trimodal Therapy Plus Atezolizumab in Muscle-invasive Bladder Cancer", "status": "UNKNOWN", "last_update": "2018-08-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03628716", "title": "CV301 Combined With PD-1/L1 Blockade in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer", "status": "COMPLETED", "last_update": "2022-04-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03650348", "title": "PRS-343 in Combination With Atezolizumab in HER2-Positive Solid Tumors", "status": "COMPLETED", "last_update": "2024-04-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03693014", "title": "A Study of Several Radiation Doses for Patients With Progression on Immunotherapy/Checkpoint Inhibitors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03697850", "title": "Atezolizumab After Chemo-radiotherapy for MIBC Patients Not Eligible for Radical Cystectomy", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-11-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03775265", "title": "Chemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-28", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03799835", "title": "Atezolizumab Plus One-year BCG Bladder Instillation in BCG-naive High-risk Non-muscle Invasive Bladder Cancer Patients", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2024-12-11", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03869190", "title": "Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatments and Combinations in Patients With Urothelial Carcinoma (MORPHEUS-UC)", "status": "TERMINATED", "last_update": "2026-08-03", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03915678", "title": "Atezolizumab Combined With BDB001 AnD Immunogenic Radiotherapy in Patients With Advanced Solid Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04045613", "title": "Derazantinib and Atezolizumab in Patients With Urothelial Cancer", "status": "COMPLETED", "last_update": "2023-10-13", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04134000", "title": "Atezolizumab and BCG in High Risk BCG na\u00efve Non-muscle Invasive Bladder Cancer (NMIBC) Patients (BladderGATE)", "status": "UNKNOWN", "last_update": "2024-05-21", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04138628", "title": "Treatment Of Metastatic Bladder Cancer at the Time Of Biochemical reLApse Following Radical Cystectomy", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-04-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04157985", "title": "Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors", "status": "COMPLETED", "last_update": "2025-12-11", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04186013", "title": "Efficacy of Atezolizumab Concurrent With Radiotherapy in Patients With Muscle-invasive Bladder c\u00e1ncer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2022-10-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04289779", "title": "Study of CAbozantinib in Combination with AtezolizumaB for Muscle-Invasive BladdEr Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2024-12-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04602078", "title": "Study of Atezolizumab Combined With Split-dose Gemcitabine Plus Cisplatin in Urothelial Carcinoma", "status": "COMPLETED", "last_update": "2025-04-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04630730", "title": "Intravesical Recombinant BCG Followed by Perioperative Chemo-immunotherapy for Patients With MIBC", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-01-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04637594", "title": "Trying to Find the Correct Length of Treatment With Immune Checkpoint Therapy", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-03-20", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04660344", "title": "A Study of Atezolizumab Versus Placebo as Adjuvant Therapy in Participants With High-risk Muscle-invasive Bladder Cancer (MIBC) Who Are ctDNA Positive Following Cystectomy", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-03-27", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04713891", "title": "A Study of KF-0210 in Advanced Solid Tumors Patients", "status": "COMPLETED", "last_update": "2024-09-24", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04902040", "title": "Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies", "status": "TERMINATED", "last_update": "2026-04-30", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05253053", "title": "To Evaluate Efficacy and Safety of TT-00420 (Tinengotinib) as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors", "status": "COMPLETED", "last_update": "2025-06-12", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05259319", "title": "Study Evaluating the Safety and the Efficacy of Combination of Atezolizumab, Tiragolumab and and Stereotactic Body Radiation Therapy in Patients With Oligometastatic Multiorgan (IMMUNOs-SBRT)", "status": "UNKNOWN", "last_update": "2023-10-17", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05429866", "title": "Immunological Variables Associated to ICI Toxicity in Cancer Patients", "status": "UNKNOWN", "last_update": "2023-03-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05564416", "title": "Testing Anti-Cancer Drugs Erdafitinib With or Without Atezolizumab in Patients With Localized Bladder Cancer Not Able to Receive Cisplatin Chemotherapy, NERA Trial", "status": "WITHDRAWN", "last_update": "2025-10-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06090318", "title": "Milademetan in Combination With Atezolizumab in Patients With Advanced Solid Tumors With CDKN2A Loss", "status": "WITHDRAWN", "last_update": "2023-10-19", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" } ] }, "AVELUMAB": { "n": 33, "n_observational": 4, "n_active": 13, "n_withdrawn": 2, "trials": [ { "nct": "NCT05267626", "title": "Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2R\u03b1 Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer", "status": "RECRUITING", "last_update": "2026-07-30", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06228066", "title": "Lurbinectedin With or Without Avelumab in Small Cell Carcinoma of the Bladder (LASER)", "status": "RECRUITING", "last_update": "2026-08-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06820255", "title": "DDR Genes Alteration and Response to Platinum-based Chemotherapy in Advanced Urothelial Cancer.", "status": "RECRUITING", "last_update": "2025-02-11", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06892860", "title": "Comparing 3 vs 6 Cycles of Platinum-based Chemotherapy Prior to Maintenance Avelumab in Advanced Urothelial Cancer", "status": "RECRUITING", "last_update": "2026-05-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01772004", "title": "Avelumab in Metastatic or Locally Advanced Solid Tumors (JAVELIN Solid Tumor)", "status": "COMPLETED", "last_update": "2021-12-20", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02554812", "title": "A Study Of Avelumab In Combination With Other Cancer Immunotherapies In Advanced Malignancies (JAVELIN Medley)", "status": "TERMINATED", "last_update": "2024-07-30", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02603432", "title": "A Study Of Avelumab In Patients With Locally Advanced Or Metastatic Urothelial Cancer (JAVELIN Bladder 100)", "status": "COMPLETED", "last_update": "2024-03-27", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03324282", "title": "First-line Gemcitabine/Cisplatin +/- Avelumab in Locally Advanced or Metastatic Bladder Carcinoma", "status": "TERMINATED", "last_update": "2026-05-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03472560", "title": "A Study of Avelumab in Combination With Axitinib In Non-Small Cell Lung Cancer (NSCLC) or Urothelial Cancer (Javelin Medley VEGF)", "status": "TERMINATED", "last_update": "2024-04-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03498196", "title": "A Window of Opportunity Trial: Avelumab in Non-metastatic Muscle Invasive Bladder Cancer", "status": "TERMINATED", "last_update": "2020-08-24", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03617913", "title": "Avelumab in Combination With Fluorouracil and Mitomycin or Cisplatin and Radiation Therapy in Treating Participants With Muscle-Invasive Bladder Cancer", "status": "COMPLETED", "last_update": "2023-01-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03674424", "title": "Avelumab as Neoadjuvant Therapy in Subjects With Urothelial Muscle Invasive Bladder Cancers (AURA Trial)", "status": "COMPLETED", "last_update": "2025-02-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03744793", "title": "Pemetrexed and Avelumab in Treating Patients With MTAP-Deficient Metastatic Urothelial Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03747419", "title": "Avelumab and Radiation in Muscle-Invasive Bladder Cancer", "status": "TERMINATED", "last_update": "2025-10-31", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03892642", "title": "Avelumab Plus Bacille Calmette-Guerin (BCG) in Patients With Non-muscle Invasive Bladder Cancer", "status": "COMPLETED", "last_update": "2024-02-14", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03915405", "title": "KHK2455 (IDO Inhibitor) Plus Avelumab in Adult Subjects With Advanced Bladder Cancer", "status": "TERMINATED", "last_update": "2024-04-25", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03950362", "title": "Bladder PREserVation by RadioTherapy and Immunotherapy in BCG Unresponsive Non-muscle Invasive Bladder Cancer", "status": "UNKNOWN", "last_update": "2019-05-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04004442", "title": "Avelumab in Combination With AVB-S6-500 in Patients With Advanced Urothelial Carcinoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-03-13", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04260802", "title": "A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers", "status": "TERMINATED", "last_update": "2026-01-12", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04637594", "title": "Trying to Find the Correct Length of Treatment With Immune Checkpoint Therapy", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-03-20", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04701918", "title": "Cryoablation With Pembrolizumab Or Avelumab In Urothelial Carcinoma", "status": "COMPLETED", "last_update": "2026-01-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04848519", "title": "Immune Checkpoint Inhibitors With or Without Propranolol Hydrochloride In Patients With Urothelial Carcinoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-02-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04871529", "title": "Testing the Addition of an Anti-Cancer Immunotherapy Drug, Avelumab, to Gemcitabine and Carboplatin Chemotherapy Prior to Surgery in Muscle Invasive Urinary Tract Cancer vs. Surgery Alone in Patients Who Are Not Able to Receive Cisplatin Therapy (SWOG GAP TRIAL)", "status": "TERMINATED", "last_update": "2024-12-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04887831", "title": "Trilaciclib, a CDK 4/6 Inhibitor, in Patients With Advanced/Metastatic Bladder Cancer Receiving Chemotherapy Then Avelumab", "status": "TERMINATED", "last_update": "2025-09-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04902040", "title": "Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies", "status": "TERMINATED", "last_update": "2026-04-30", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05092958", "title": "Testing the Addition of the Anti-cancer Drug, Cabozantinib, to the Usual Immunotherapy Treatment, Avelumab, in Patients With Metastatic Urothelial Cancer, MAIN-CAV Study", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-12", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05327530", "title": "A Study of the Safety and Efficacy of Various Combinations of Avelumab as Therapy in Locally Advanced or Metastatic Urothelial Carcinoma (JAVELIN Bladder Medley)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05429866", "title": "Immunological Variables Associated to ICI Toxicity in Cancer Patients", "status": "UNKNOWN", "last_update": "2023-03-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05687721", "title": "Copanlisib and Avelumab as a Maintenance Therapy for Advanced Bladder Cancer", "status": "WITHDRAWN", "last_update": "2025-06-15", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06204614", "title": "Drug Screening Using IMD in Bladder Cancer", "status": "ENROLLING_BY_INVITATION", "last_update": "2026-05-18", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06225596", "title": "Study BT8009-230 in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06424717", "title": "Study of Avelumab and Tuvusertib in Participants With Advanced Urothelial Cancer That Has Progressed on Prior Anti-PD-(L)1 Therapy (JAVELIN DDRiver Bladder)", "status": "WITHDRAWN", "last_update": "2024-09-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06686381", "title": "Tetra-modality Bladder Preservation Strategies in Muscle-invasive Bladder Cancer: TURBT+ Chemo/Immunotherapy+ Radiation Therapy+ Maintenance Immunotherapy vs. W&W", "status": "NOT_YET_RECRUITING", "last_update": "2025-02-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "BINTRAFUSP ALFA": { "n": 2, "n_observational": 0, "n_active": 1, "n_withdrawn": 0, "trials": [ { "nct": "NCT04235777", "title": "Bintrafusp Alfa (M7824) and PDS01ADC Alone and in Combination With Stereotactic Body Radiation Therapy (SBRT) in Adults With Metastatic Non-Prostate Genitourinary Malignancies", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-08", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04878250", "title": "Preoperative Bintrafusp Alfa in Operable Urothelial Carcinoma of the Bladder", "status": "UNKNOWN", "last_update": "2021-05-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "CONTUSUGENE LADENOVEC": { "n": 1, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT00003167", "title": "Gene Therapy in Treating Patients With Advanced Bladder Cancer", "status": "COMPLETED", "last_update": "2013-01-23", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ] }, "COPANLISIB": { "n": 3, "n_observational": 0, "n_active": 1, "n_withdrawn": 1, "trials": [ { "nct": "NCT02465060", "title": "Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02631590", "title": "Copanlisib (BAY 80-6946) in Combination With Gemcitabine and Cisplatin in Advanced Cholangiocarcinoma", "status": "COMPLETED", "last_update": "2021-08-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05687721", "title": "Copanlisib and Avelumab as a Maintenance Therapy for Advanced Bladder Cancer", "status": "WITHDRAWN", "last_update": "2025-06-15", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" } ] }, "DATOPOTAMAB DERUXTECAN": { "n": 3, "n_observational": 0, "n_active": 3, "n_withdrawn": 0, "trials": [ { "nct": "NCT07129993", "title": "Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma", "status": "RECRUITING", "last_update": "2026-08-20", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07720284", "title": "An Open-label Study to Investigate the Efficacy and Safety of Dato-DXd + Rilvegostomig vs SoC in Adult Participants With High-risk MIUC", "status": "RECRUITING", "last_update": "2026-07-22", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04644068", "title": "Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-19", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" } ] }, "DERAZANTINIB": { "n": 1, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT04045613", "title": "Derazantinib and Atezolizumab in Patients With Urothelial Cancer", "status": "COMPLETED", "last_update": "2023-10-13", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" } ] }, "DISITAMAB VEDOTIN": { "n": 26, "n_observational": 0, "n_active": 18, "n_withdrawn": 0, "trials": [ { "nct": "NCT04879329", "title": "A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2", "status": "RECRUITING", "last_update": "2026-07-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06378242", "title": "To Evaluate the Safety, Efficacy, and Pharmacokinetics of Intravesical Instiliations of Disitamab Vedotin in Patients With High-risk Non-muscular Invasive Bladder Cancer (NMIBC) That Express HER2", "status": "RECRUITING", "last_update": "2024-07-11", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07207824", "title": "DV+BCG in HER2-Expressing, BCG-Na\u00efve High-Risk NMIBC", "status": "RECRUITING", "last_update": "2026-07-21", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07646145", "title": "Disitamab Vedotin Plus Intravesical Mitomycin C in HER2-Expressing Intermediate- to High-Risk Non-Muscle-Invasive Bladder Cancer", "status": "RECRUITING", "last_update": "2026-06-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07717242", "title": "Sun Yat-Sen Treatment Strategy for Enhancing Response in Muscle-invasive Bladder Cancer", "status": "RECRUITING", "last_update": "2026-07-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05016973", "title": "A Clinical Study of RC48-ADC Combined With Triplizumab For Treatment of Myometrial Invasive Bladder Cancer", "status": "UNKNOWN", "last_update": "2021-08-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05488353", "title": "A Clinical Study of Disitamab Vedotin for Injection Combined With Penpulimab Injection in Neoadjuvant Therapy for Patients With HER2-expressing Cisplatin-intolerant cT2-T4aNxM0 Bladder Urothelial Carcinoma", "status": "UNKNOWN", "last_update": "2022-08-04", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05495724", "title": "Disitamab Vedotin Combined With Tislelizumab for Her2 Overexpressing High-Risk Non-Muscle-Invasive Urothelial Bladder Carcinoma Which is Not Completely Resectable", "status": "UNKNOWN", "last_update": "2022-08-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05723991", "title": "Study of Disitamab Vedotin Combined With Gemcitabine in Neoadjuvant Treatment of Urothelial Carcinoma", "status": "UNKNOWN", "last_update": "2023-02-13", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05911295", "title": "Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-22", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05912205", "title": "Disitamab Vedotin Combined With Radiotherapy for Bladder Preservation", "status": "UNKNOWN", "last_update": "2023-06-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05957757", "title": "RC48 Combined With Tislelizumab for Bladder Sparing Treatment in NMIBC With BCG Treatment Failure and HER2 Expression", "status": "UNKNOWN", "last_update": "2023-08-31", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05979740", "title": "RC48 Combined With Toripalimab and Radiotherapy for Bladder Sparing Treatment in MIBC", "status": "UNKNOWN", "last_update": "2023-08-31", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06074484", "title": "A Study of RC48-ADC Combined With AK104 For Perioperative Treatment of Muscle-Invasive Bladder Cancer", "status": "UNKNOWN", "last_update": "2023-10-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06187506", "title": "Disitamab Vedotin Combined With BCG Therapy in HER2-expressing High-risk Non-muscle Invasive Bladder Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06630871", "title": "A Clinical Trial Evaluating the Efficacy and Safety of Disitamab Vedotin Plus Tislelizumab Combined with Re-TURBT in the Treatment of HER-2-high Expression(2+-3+) Non-muscle Invasive Bladder Cancer At High-risk and Very High-risk.", "status": "NOT_YET_RECRUITING", "last_update": "2024-10-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06957561", "title": "Disitamab Vedotin Combined With Ivonescimab in Cisplatin-Ineligible Muscle-Invasive Bladder Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2025-05-04", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07100184", "title": "RC48 in Combination With Radiotherapy for HER2-Expressing NMIBC Patients", "status": "NOT_YET_RECRUITING", "last_update": "2025-08-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07142200", "title": "A Clinical Study Evaluating the Efficacy and Safety of Disitamab Vedotin Combined With PD-1 Inhibitor and Radiotherapy as Bladder-preserving Therapy in Patients With Localized HER2-high Expressing Muscle-invasive Bladder Urothelial Carcinoma Following Maximal Transurethral Resection", "status": "NOT_YET_RECRUITING", "last_update": "2025-08-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07151560", "title": "Efficacy and Safety of Two Bladder-preserving Treatment Durations With Disitamab Vedotin Plus Toripalimab Combination in Her2-expressing Muscle-invasive Bladder Cancer: A Phase II, Open-Label, Randomized Clinical Trial", "status": "NOT_YET_RECRUITING", "last_update": "2025-09-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07474064", "title": "Probiotics Combined With Targeted Therapy Plus Immunotherapy in Bladder-Preserving Setting for Patients With MIBC", "status": "NOT_YET_RECRUITING", "last_update": "2026-03-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07608224", "title": "HOPE-07-MIBC: Disitamab Vedotin Plus Immunotherapy vs Chemoimmunotherapy in Resectable HER2-Expressing MIBC", "status": "NOT_YET_RECRUITING", "last_update": "2026-05-27", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07662863", "title": "Sacituzumab Tirumotecan vs MMAE-ADCs in Advanced Urothelial Carcinoma (FUSCC-SPARE-UC-01)", "status": "NOT_YET_RECRUITING", "last_update": "2026-06-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07690878", "title": "PTC-guided Neoadjuvant Therapy For Muscle-invasive Bladder Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2026-07-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07756008", "title": "Bladder-Sparing Treatment With Disitamab Vedotin and Toripalimab With or Without Pelvic Lymph Node Dissection in Bladder Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2026-08-10", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07783815", "title": "A Study to Evaluate the Efficacy and Safety of Intravesical Instillation of Disitamab Vedotin Combined With Toripalimab in Patients With HER2-Positive High-Risk Non-Muscle Invasive Bladder Cancer Who Are BCG-Na\u00efve or Have BCG Failure", "status": "NOT_YET_RECRUITING", "last_update": "2026-08-25", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ] }, "DOVITINIB": { "n": 2, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT01496534", "title": "Phase Ib Study of Gemcitabine Plus Cisplatin or Carboplatin Plus Dovitinib in Patients With Advanced Solid Tumors", "status": "TERMINATED", "last_update": "2013-11-27", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01732107", "title": "Dovitinib in BCG Refractory Urothelial Carcinoma With FGFR3 Mutations or Over-expression", "status": "TERMINATED", "last_update": "2022-07-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "DURVALUMAB": { "n": 48, "n_observational": 0, "n_active": 23, "n_withdrawn": 3, "trials": [ { "nct": "NCT04106115", "title": "DURvalumab in Combination With S-488210/S-488211 vAccine in Non-muscle Invasive Bladder CancEr", "status": "RECRUITING", "last_update": "2026-06-11", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06214572", "title": "Radiation Therapy in Unresectable Gall Bladder Cancer", "status": "RECRUITING", "last_update": "2025-04-11", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06263153", "title": "Futibatinib in Combination With Durvalumab Prior to Cystectomy for the Treatment of Muscle-Invasive Bladder Cancer Patients Who Are Ineligible for Cisplatin-based Therapy", "status": "RECRUITING", "last_update": "2025-12-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06503614", "title": "A Trial of Durvalumab (MEDI4736) Plus Monalizumab in Non-Muscle-Invasive Bladder Cancer", "status": "RECRUITING", "last_update": "2026-04-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06960577", "title": "Perioperative Durvalumab With Neoadjuvant ddMVAC or Gemcitabine/Cisplatin in Patients With Muscle-invasive Bladder Cancer (NIAGARA-2)", "status": "RECRUITING", "last_update": "2026-08-04", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06963346", "title": "Study Investigating Intravesical HDAC Inhibition to Improve Response to Immuno-Oncology Agents", "status": "RECRUITING", "last_update": "2026-07-30", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07720284", "title": "An Open-label Study to Investigate the Efficacy and Safety of Dato-DXd + Rilvegostomig vs SoC in Adult Participants With High-risk MIUC", "status": "RECRUITING", "last_update": "2026-07-22", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02527434", "title": "Study of Tremelimumab in Patients With Advanced Solid Tumors", "status": "COMPLETED", "last_update": "2023-11-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02546661", "title": "Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Phase 1b Study in Pts w/ Muscle Invasive Bladder Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-12-29", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02643303", "title": "A Study of Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible Cancers", "status": "COMPLETED", "last_update": "2022-12-02", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02812420", "title": "Durvalumab and Tremelimumab in Treating Patients With Muscle-Invasive, High-Risk Urothelial Cancer That Cannot Be Treated With Cisplatin-Based Therapy Before Surgery", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-03-05", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02891161", "title": "Durvalumab And Radiation Therapy Followed by Adjuvant Durvalumab in Patients With Urothelial Cancer (T2-4 N0-2 M0) of the Bladder", "status": "TERMINATED", "last_update": "2024-11-27", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02901548", "title": "Phase 2 Durvalumab (Medi4736) for Bacillus Calmette-Gu\u00e9rin (BCG) Refactory Urothelial Carcinoma in Situ of the Bladder", "status": "TERMINATED", "last_update": "2022-07-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03150836", "title": "Radiation Therapy and Durvalumab, With or Without Tremelimumab, in Patients With Bladder Cancer", "status": "WITHDRAWN", "last_update": "2017-10-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03234153", "title": "Neoadjuvant Immunotherapy With Durvalumab and Tremelimumab for Bladder Cancer Patients Ineligible for Cisplatin", "status": "TERMINATED", "last_update": "2020-06-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03258593", "title": "Durvalumab and Vicineum in Subjects With High-Grade Non-Muscle-Invasive Bladder Cancer Previously Treated With Bacillus Calmette-Guerin (BCG)", "status": "COMPLETED", "last_update": "2026-08-25", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03317158", "title": "Modern Immunotherapy in BCG-Unresponsive, BCG-Relapsing and High Risk BCG-Naive Non-Muscle Invasive Urothelial Carcinoma of the Bladder", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-15", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03406650", "title": "Neoadjuvant and Adjuvant Durvalumab in Combination With Neoadjuvant Chemotherapy in Patients With Operable Urothelial Cancer.", "status": "COMPLETED", "last_update": "2025-05-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03430895", "title": "Evaluating Immune Therapy, Durvalumab (MEDI4736) With Tremelimumab for Metastatic, Non-transitional Cell Carcinoma of the Urinary Tract", "status": "COMPLETED", "last_update": "2021-12-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03459846", "title": "A Study of Durvalumab Alone and Durvalumab+Olaparib in Advanced, Platinum-Ineligible Bladder Cancer (BAYOU)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03472274", "title": "Durvalumab (MEDI4736) and TREmelimumab in NEOadjuvant Bladder Cancer Patients (DUTRENEO)", "status": "COMPLETED", "last_update": "2023-04-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03473574", "title": "Durvalumab and Tremelimumab With Gemcitabine or Gemcitabine/Cisplatin Compared to Gemcitabine/Cisplatin in CCA Patients", "status": "COMPLETED", "last_update": "2023-06-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03528694", "title": "Assessment of Efficacy and Safety of Durvalumab Plus BCG Compared to the Standard Therapy With BCG in Non-muscle Invasive Bladder Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-07", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03534492", "title": "Durvalumab Plus Olaparib Administered Prior to Surgery of Resectable Urothelial Bladder Cancer (NEODURVARIB)", "status": "COMPLETED", "last_update": "2020-04-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03601455", "title": "Radiation Therapy and Durvalumab With or Without Tremelimumab in Treating Participants With Unresectable, Locally Advanced, or Metastatic Bladder Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03682068", "title": "Study of Durvalumab Given With Chemotherapy, Durvalumab in Combination With Tremelimumab Given With Chemotherapy, or Chemotherapy in Patients With Unresectable Urothelial Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-20", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03702179", "title": "Durvalumab Plus Tremelimumab With Concurrent Radiotherapy for Localized Muscle Invasive Bladder Cancer Treated With a Selective Bladder Preservation Approach", "status": "COMPLETED", "last_update": "2024-12-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03732677", "title": "Durvalumab+ Gemcitabine/Cisplatin (Neoadjuvant Treatment) and Durvalumab (Adjuvant Treatment) in Patients With MIBC", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-17", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03759496", "title": "Efficacy of Durvalumab in Non-muscle-invasive Bladder Cancer", "status": "UNKNOWN", "last_update": "2022-03-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03768570", "title": "Trimodality Therapy With/Out Durvalumab to Treat Patients With Muscle-Invasive Bladder Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03773666", "title": "A Feasibility Study of Durvalumab +/- Oleclumab as Neoadjuvant Therapy for Muscle-invasive Bladder Cancer (BLASST-2)", "status": "COMPLETED", "last_update": "2022-09-13", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03824691", "title": "hARnessing CAbozantinib and Durvalumab Immuno-oncology Association: ARCADIA Study\"", "status": "UNKNOWN", "last_update": "2021-02-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03912818", "title": "Durvalumab and Standard Chemotherapy Before Surgery in Treating Patients With Variant Histology Bladder Cancer", "status": "TERMINATED", "last_update": "2023-09-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03983954", "title": "Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumor, Including a Cohort Expansion in Esophageal Cancer.", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-11-28", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04073160", "title": "TRIO Bladder: A Study of Durvalumab Plus Tremelimumab Followed by Concurrent Durvalumab Plus Bladder Radiation in Muscle-Invasive Bladder Cancer", "status": "WITHDRAWN", "last_update": "2020-07-07", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04216290", "title": "A Study of Chemotherapy and Radiation Therapy Compared to Chemotherapy and Radiation Therapy Plus MEDI4736 (Durvalumab) Immunotherapy for Bladder Cancer Which Has Spread to the Lymph Nodes, INSPIRE Trial", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04543110", "title": "Radiation and Durvalumab Immunotherapy As Neoadjuvant Treatment for MIBC", "status": "UNKNOWN", "last_update": "2023-03-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04579133", "title": "Neoadjuvant Durvalumab Alone Versus Durvalumab With Olaparib in Patients Ineligible for Cisplatin With Muscle-Invasive Urothelial Carcinoma of the Bladder Followed by Radical Cystectomy", "status": "TERMINATED", "last_update": "2021-06-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04637594", "title": "Trying to Find the Correct Length of Treatment With Immune Checkpoint Therapy", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-03-20", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04902040", "title": "Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies", "status": "TERMINATED", "last_update": "2026-04-30", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04960709", "title": "Treatment Combination of Durvalumab, Tremelimumab and Enfortumab Vedotin or Durvalumab and Enfortumab Vedotin in Patients With Muscle Invasive Bladder Cancer Ineligible to Cisplatin or Who Refuse Cisplatin", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-04", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05120622", "title": "Trial of Local Cystoscopic Injection of Tremelimumab Plus Systemic Durvalumab for High Risk Non-Muscle Invasive Bladder Cancer", "status": "WITHDRAWN", "last_update": "2023-10-31", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05137262", "title": "A Phase II Multicenter Study of Chemotherapy Versus Chemotherapy Plus Durvalumab (MEDI 4736) in Patients With Lymph Node Positive Urothelial Carcinoma of the Bladder", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05239169", "title": "Immunotherapy With Durva and Treme With or Without Capecitabine in Adjuvant Treatment for Biliary Tract Cancer", "status": "COMPLETED", "last_update": "2025-05-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05429866", "title": "Immunological Variables Associated to ICI Toxicity in Cancer Patients", "status": "UNKNOWN", "last_update": "2023-03-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05712356", "title": "A Study of LSTA1 When Added to Standard of Care Versus Standard of Care Alone in Patients With Advanced Solid Tumors", "status": "TERMINATED", "last_update": "2026-05-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05943106", "title": "BCG in Combination With Durvalumab in Adult BCG-na\u00efve, High-risk NMIBC Participants", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-13", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07332351", "title": "Neoadjuvant Intravesical Nadofaragene Firadenovec With Gemcitabine, Cisplatin and Durvalumab for the Treatment of Muscle Invasive Bladder Cancer, TRIFECTA Trial", "status": "NOT_YET_RECRUITING", "last_update": "2026-06-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "ENFORTUMAB VEDOTIN": { "n": 45, "n_observational": 3, "n_active": 38, "n_withdrawn": 0, "trials": [ { "nct": "NCT04724018", "title": "Sacituzumab Govitecan Plus EV in Metastatic UC", "status": "RECRUITING", "last_update": "2025-11-04", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04878029", "title": "Cabozantinib in Combination With Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial Cancer", "status": "RECRUITING", "last_update": "2026-04-29", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05126472", "title": "Study of 2141-V11 in People With Non-muscle Invasive Bladder Cancer That Did Not Respond to Standard Treatment", "status": "RECRUITING", "last_update": "2026-08-14", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05239624", "title": "Enfortumab Vedotin and Pembrolizumab in People With Bladder Cancer", "status": "RECRUITING", "last_update": "2026-06-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05614739", "title": "FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3", "status": "RECRUITING", "last_update": "2026-08-20", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05656235", "title": "Renal Retention in High Grade Upper Tract Urothelial Cancer", "status": "RECRUITING", "last_update": "2026-01-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05756569", "title": "Enfortumab Vedotin Plus Pembrolizumab for the Treatment of Locally Advanced or Metastatic Bladder Cancer of Variant Histology", "status": "RECRUITING", "last_update": "2026-07-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05879653", "title": "Pembrolizumab and EV With Radiation Therapy for MIBC Patients (PEVRAD)", "status": "RECRUITING", "last_update": "2025-08-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06041503", "title": "Enfortumab Vedotin With or Without Pembrolizumab in Rare Genitourinary Tumors (E-VIRTUE)", "status": "RECRUITING", "last_update": "2026-08-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06394570", "title": "Enfortumab Vedotin and Stereotactic Radiation for Localized, Cisplatin Ineligible Muscle Invasive Bladder Cancer", "status": "RECRUITING", "last_update": "2025-09-15", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06434350", "title": "Enfortumab Vedotin With Radiation for Locally Advanced Bladder Cancer (CONSOLIDATE)", "status": "RECRUITING", "last_update": "2026-06-15", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06470282", "title": "Enfortumab Vedotin and Pembrolizumab Combined With Radiotherapy in Muscle Invasive Bladder Cancer", "status": "RECRUITING", "last_update": "2026-02-18", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06493552", "title": "Modular Trial of sEphB4-HSA in EphrinB2-High Solid Tumors", "status": "RECRUITING", "last_update": "2025-04-03", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06764095", "title": "Enfortumab Vedotin and Pembrolizumab With Cystectomy and/or Ureterectomy for Locally Advanced or Metastatic Bladder and Upper Urothelial Tract Cancer, CAST-AI Trial", "status": "RECRUITING", "last_update": "2026-02-12", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06809140", "title": "Enfortumab Vedotin Plus Pembrolizumab With Selective Bladder Sparing for Treatment of Muscle-invasive Bladder Cancer", "status": "RECRUITING", "last_update": "2026-08-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07087860", "title": "Therapeutic Plasma Exchange With Enfortumab Vedotin and Pembrolizumab for Treatment of Bladder Cancers", "status": "RECRUITING", "last_update": "2026-05-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07129993", "title": "Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma", "status": "RECRUITING", "last_update": "2026-08-20", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07218380", "title": "A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract", "status": "RECRUITING", "last_update": "2026-08-21", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07232602", "title": "KEYMAKER-U04 Substudy 04D: A Clinical Study of New Treatments Given With Enfortumab Vedotin and Pembrolizumab in People With Urothelial Cancer (MK-3475-04D/KEYMAKER-U04)", "status": "RECRUITING", "last_update": "2026-09-01", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07421700", "title": "Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer", "status": "RECRUITING", "last_update": "2026-08-17", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07475806", "title": "A Study to Find Out if Enfortumab Vedotin Given With Pembrolizumab Helps People With Muscle-invasive Bladder Cancer Keep Their Bladder", "status": "RECRUITING", "last_update": "2026-08-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07548476", "title": "Acupuncture and Exercise for EV-Pembro-Induced Peripheral Neuropathy", "status": "RECRUITING", "last_update": "2026-09-10", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07566156", "title": "Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invasive Bladder Cancer (EV-309)", "status": "RECRUITING", "last_update": "2026-09-11", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07579195", "title": "Consolidative Therapy After EV + Pembrolizumab in Muscle Invasive Bladder Cancer, REINFORCE Trial", "status": "RECRUITING", "last_update": "2026-08-25", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07647289", "title": "EV + Toripalimab vs GC as Neoadjuvant Therapy in Locally Advanced/High-Risk MIBC", "status": "RECRUITING", "last_update": "2026-06-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07720284", "title": "An Open-label Study to Investigate the Efficacy and Safety of Dato-DXd + Rilvegostomig vs SoC in Adult Participants With High-risk MIUC", "status": "RECRUITING", "last_update": "2026-07-22", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03219333", "title": "A Study of Enfortumab Vedotin for Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer", "status": "COMPLETED", "last_update": "2024-08-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03288545", "title": "A Study of Enfortumab Vedotin Alone or With Other Therapies for Treatment of Urothelial Cancer", "status": "TERMINATED", "last_update": "2026-03-24", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03474107", "title": "A Study to Evaluate Enfortumab Vedotin Versus (vs) Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer (EV-301)", "status": "COMPLETED", "last_update": "2026-01-09", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03606174", "title": "A Phase 2 Study of Sitravatinib in Combination With PD-(L)1 Checkpoint Inhibitor Regimens in Patients With Advanced or Metastatic Urothelial Carcinoma", "status": "TERMINATED", "last_update": "2023-08-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03869190", "title": "Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatments and Combinations in Patients With Urothelial Carcinoma (MORPHEUS-UC)", "status": "TERMINATED", "last_update": "2026-08-03", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03924895", "title": "Perioperative Pembrolizumab (MK-3475) Plus Cystectomy or Perioperative Pembrolizumab Plus Enfortumab Vedotin Plus Cystectomy Versus Cystectomy Alone in Participants Who Are Cisplatin-ineligible or Decline Cisplatin With Muscle-invasive Bladder Cancer (MK-3475-905/KEYNOTE-905/EV-303)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-30", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04700124", "title": "Perioperative Enfortumab Vedotin (EV) Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Chemotherapy for Cisplatin-Eligible Muscle Invasive Bladder Cancer (MIBC) (MK-3475-B15/ KEYNOTE-B15 / EV-304)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-16", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04960709", "title": "Treatment Combination of Durvalumab, Tremelimumab and Enfortumab Vedotin or Durvalumab and Enfortumab Vedotin in Patients With Muscle Invasive Bladder Cancer Ineligible to Cisplatin or Who Refuse Cisplatin", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-04", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04963153", "title": "Testing Combination Erdafitinib and Enfortumab Vedotin in Metastatic Bladder Cancer After Treatment With Chemotherapy and Immunotherapy", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-31", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05014139", "title": "A Study of Intravesical Enfortumab Vedotin For Treatment of Patients With Non-muscle Invasive Bladder Cancer (NMIBC)", "status": "TERMINATED", "last_update": "2025-11-20", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05524545", "title": "A Study of Evorpacept (ALX148) With Enfortumab Vedotin for Subjects With Urothelial Carcinoma (ASPEN-07)", "status": "COMPLETED", "last_update": "2025-07-25", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06204614", "title": "Drug Screening Using IMD in Bladder Cancer", "status": "ENROLLING_BY_INVITATION", "last_update": "2026-05-18", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06305767", "title": "A Clinical Study of Intismeran Autogene (V940) Treatment and Pembrolizumab in People With Bladder Cancer (V940-005/INTerpath-005)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-01-13", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07346053", "title": "The Impact of Time-of-day Administration of EV/P on Objective Response Rate in Adults With Advanced Bladder Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2026-01-16", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07643519", "title": "Neoadjuvant Enfortumab Vedotin Plus Pembrolizumab in Muscle-Invasive Bladder Cancer and Upper Tract Urothelial Carcinoma", "status": "NOT_YET_RECRUITING", "last_update": "2026-06-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07662863", "title": "Sacituzumab Tirumotecan vs MMAE-ADCs in Advanced Urothelial Carcinoma (FUSCC-SPARE-UC-01)", "status": "NOT_YET_RECRUITING", "last_update": "2026-06-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07663747", "title": "Enfortumab Vedotin + Pembrolizumab Induction to Spare the Bladder in MIBC", "status": "NOT_YET_RECRUITING", "last_update": "2026-06-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07667335", "title": "Enfortumab Vedotin, Pembrolizumab and Quemliclustat for the Treatment of Unresectable Locally Advanced and Metastatic Urothelial Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2026-09-04", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07690878", "title": "PTC-guided Neoadjuvant Therapy For Muscle-invasive Bladder Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2026-07-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "EPRENETAPOPT": { "n": 1, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT04383938", "title": "Phase 1/2 Study of APR-246 in Combination With Pembrolizumab in Subjects With Solid Tumor Malignancies", "status": "COMPLETED", "last_update": "2025-05-13", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" } ] }, "ERDAFITINIB": { "n": 11, "n_observational": 2, "n_active": 9, "n_withdrawn": 1, "trials": [ { "nct": "NCT06319820", "title": "A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer", "status": "RECRUITING", "last_update": "2026-08-28", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06511648", "title": "Erdafitinib Monotherapy or in Combination With Cetrelimab in Muscle-invasive Bladder Cancer Patients With Fibroblast Growth Factor Receptor (FGFR ) Gene Alterations", "status": "RECRUITING", "last_update": "2025-12-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06919965", "title": "A Study to Evaluate TAR-210 Versus Intravesical Chemotherapy Treatment in Participants With High Risk Non-Muscle-Invasive Bladder Cancer", "status": "RECRUITING", "last_update": "2026-08-28", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02465060", "title": "Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04172675", "title": "A Study of Erdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gu\u00e9rin (BCG) and Recurred With High Risk Non-Muscle-Invasive Bladder Cancer (NMIBC)", "status": "COMPLETED", "last_update": "2026-02-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04917809", "title": "A Study of Oral Erdafitinib in People With Recurrent Non-Invasive Bladder Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04963153", "title": "Testing Combination Erdafitinib and Enfortumab Vedotin in Metastatic Bladder Cancer After Treatment With Chemotherapy and Immunotherapy", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-31", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05316155", "title": "Study of Erdafitinib Intravesical Delivery System for Localized Bladder Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-28", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05564416", "title": "Testing Anti-Cancer Drugs Erdafitinib With or Without Atezolizumab in Patients With Localized Bladder Cancer Not Able to Receive Cisplatin Chemotherapy, NERA Trial", "status": "WITHDRAWN", "last_update": "2025-10-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05567185", "title": "A Study of Erdafitinib Intravesical Delivery System in Japanese Participants With Bladder Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-28", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06204614", "title": "Drug Screening Using IMD in Bladder Cancer", "status": "ENROLLING_BY_INVITATION", "last_update": "2026-05-18", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" } ] }, "FEXAGRATINIB": { "n": 1, "n_observational": 0, "n_active": 1, "n_withdrawn": 0, "trials": [ { "nct": "NCT02465060", "title": "Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "FUTIBATINIB": { "n": 1, "n_observational": 0, "n_active": 1, "n_withdrawn": 0, "trials": [ { "nct": "NCT06263153", "title": "Futibatinib in Combination With Durvalumab Prior to Cystectomy for the Treatment of Muscle-Invasive Bladder Cancer Patients Who Are Ineligible for Cisplatin-based Therapy", "status": "RECRUITING", "last_update": "2025-12-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "INFIGRATINIB": { "n": 4, "n_observational": 0, "n_active": 0, "n_withdrawn": 1, "trials": [ { "nct": "NCT01004224", "title": "A Dose Escalation Study in Adult Patients With Advanced Solid Malignancies", "status": "COMPLETED", "last_update": "2019-10-04", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02657486", "title": "BGJ398 in Non-Muscle-Invasive Urothelial Carcinoma of the Bladder", "status": "COMPLETED", "last_update": "2026-09-02", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04197986", "title": "Oral Infigratinib for the Adjuvant Treatment of Subjects With Invasive Urothelial Carcinoma With Susceptible FGFR3 Genetic Alterations", "status": "TERMINATED", "last_update": "2024-03-13", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04972253", "title": "Phase I BLASST-3 Trial", "status": "WITHDRAWN", "last_update": "2022-08-10", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ] }, "LAPATINIB": { "n": 8, "n_observational": 0, "n_active": 0, "n_withdrawn": 1, "trials": [ { "nct": "NCT00313599", "title": "Lapatinib and Paclitaxel in Treating Patients With Advanced Solid Tumors", "status": "COMPLETED", "last_update": "2014-07-02", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00447226", "title": "Randomized Discontinuation Study of Lapatinib Versus Placebo in Subjects With Documented Tumor Progression After Chemotherapy, or Where no Approved Therapy Exists", "status": "TERMINATED", "last_update": "2012-06-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00623064", "title": "Lapatinib, Cisplatin, Gemcitabine as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Urothelial Cancer", "status": "COMPLETED", "last_update": "2014-07-01", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00949455", "title": "A Double Blind Randomised Study of Lapatinib and Placebo in Metastatic TCC of the Urothelium", "status": "UNKNOWN", "last_update": "2015-04-15", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01245660", "title": "A Phase 0 of Neoadjuvant Lapatinib in Infiltrative Bladder Carcinoma Before Cystectomy", "status": "TERMINATED", "last_update": "2013-01-11", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01382706", "title": "Docetaxel and Lapatinib in Metastatic Transitional Cell Carcinoma in Bladder", "status": "TERMINATED", "last_update": "2025-10-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01700010", "title": "Trial of Lapatinib and Weekly Paclitaxel for Advanced Urothelial Cancer", "status": "WITHDRAWN", "last_update": "2013-01-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02788201", "title": "Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma", "status": "COMPLETED", "last_update": "2020-11-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "LAPATINIB DITOSYLATE": { "n": 8, "n_observational": 0, "n_active": 0, "n_withdrawn": 1, "trials": [ { "nct": "NCT00313599", "title": "Lapatinib and Paclitaxel in Treating Patients With Advanced Solid Tumors", "status": "COMPLETED", "last_update": "2014-07-02", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00447226", "title": "Randomized Discontinuation Study of Lapatinib Versus Placebo in Subjects With Documented Tumor Progression After Chemotherapy, or Where no Approved Therapy Exists", "status": "TERMINATED", "last_update": "2012-06-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00623064", "title": "Lapatinib, Cisplatin, Gemcitabine as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Urothelial Cancer", "status": "COMPLETED", "last_update": "2014-07-01", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00949455", "title": "A Double Blind Randomised Study of Lapatinib and Placebo in Metastatic TCC of the Urothelium", "status": "UNKNOWN", "last_update": "2015-04-15", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01245660", "title": "A Phase 0 of Neoadjuvant Lapatinib in Infiltrative Bladder Carcinoma Before Cystectomy", "status": "TERMINATED", "last_update": "2013-01-11", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01382706", "title": "Docetaxel and Lapatinib in Metastatic Transitional Cell Carcinoma in Bladder", "status": "TERMINATED", "last_update": "2025-10-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01700010", "title": "Trial of Lapatinib and Weekly Paclitaxel for Advanced Urothelial Cancer", "status": "WITHDRAWN", "last_update": "2013-01-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02788201", "title": "Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma", "status": "COMPLETED", "last_update": "2020-11-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "NERATINIB": { "n": 0, "n_observational": 1, "n_active": 0, "n_withdrawn": 0, "trials": [] }, "NINTEDANIB": { "n": 1, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT02278978", "title": "BIBF1120 in Patients With Advanced FGFR3 Mutated,Overexpressed,or Wild Type Urothelial Carcinoma", "status": "UNKNOWN", "last_update": "2015-05-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "NINTEDANIB ESYLATE": { "n": 1, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT02278978", "title": "BIBF1120 in Patients With Advanced FGFR3 Mutated,Overexpressed,or Wild Type Urothelial Carcinoma", "status": "UNKNOWN", "last_update": "2015-05-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "OMIPALISIB": { "n": 1, "n_observational": 0, "n_active": 1, "n_withdrawn": 0, "trials": [ { "nct": "NCT02465060", "title": "Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "PAZOPANIB": { "n": 6, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT00471536", "title": "Pazopanib in Treating Patients With Metastatic Urothelial Cancer", "status": "COMPLETED", "last_update": "2014-05-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01031875", "title": "Pazopanib Hydrochloride in Treating Patients With Metastatic Urethral Cancer or Bladder Cancer That Has Relapsed or Not Responded to Treatment", "status": "COMPLETED", "last_update": "2013-08-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01108055", "title": "Phase II Pazopanib in Combination With Weekly Paclitaxel in Refractory Urothelial Cancer", "status": "COMPLETED", "last_update": "2017-06-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01265940", "title": "Pazopanib and Vinflunine in Urothelial Cancer of the Bladder", "status": "COMPLETED", "last_update": "2012-10-10", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01622660", "title": "Gemcitabine and Pazopanib in Chemotherapy Na\u00efve Patients With Advanced/Metastatic Urothelial Carcinoma Ineligible for Cisplatin-based Chemotherapy", "status": "TERMINATED", "last_update": "2017-08-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02788201", "title": "Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma", "status": "COMPLETED", "last_update": "2020-11-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "PEMIGATINIB": { "n": 1, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT03914794", "title": "A Study of Pemigatinib in Non-muscle Invasive Bladder Cancer Patients With Recurrent Low- or Intermediate-Risk Tumors", "status": "COMPLETED", "last_update": "2025-10-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "PERTUZUMAB": { "n": 3, "n_observational": 0, "n_active": 2, "n_withdrawn": 0, "trials": [ { "nct": "NCT05786716", "title": "DETERMINE Trial Treatment Arm 04: Trastuzumab in Combination With Pertuzumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With HER2 Amplification or Activating Mutations", "status": "RECRUITING", "last_update": "2025-12-02", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02091141", "title": "My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors", "status": "COMPLETED", "last_update": "2024-07-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02465060", "title": "Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "ROGARATINIB": { "n": 3, "n_observational": 0, "n_active": 0, "n_withdrawn": 1, "trials": [ { "nct": "NCT01976741", "title": "Dose Escalation Pan-FGFR (Fibroblast Growth Factor Receptor) Inhibitor (Rogaratinib)", "status": "COMPLETED", "last_update": "2021-05-06", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03473756", "title": "Phase 1b/2 Study of Rogaratinib (BAY1163877) in Combination With Atezolizumab in Urothelial Carcinoma", "status": "COMPLETED", "last_update": "2025-04-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04040725", "title": "Rogaratinib for BCG Refractory High Risk Non-Muscle Invasive Bladder Cancer With FGFR1/2 Overexpression", "status": "WITHDRAWN", "last_update": "2019-12-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "SACITUZUMAB GOVITECAN": { "n": 17, "n_observational": 0, "n_active": 13, "n_withdrawn": 0, "trials": [ { "nct": "NCT04724018", "title": "Sacituzumab Govitecan Plus EV in Metastatic UC", "status": "RECRUITING", "last_update": "2025-11-04", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05833867", "title": "Adaptive RADiation Therapy With Concurrent Sacituzumab Govitecan (SG) for Muscle Invasive Bladder Cancer", "status": "RECRUITING", "last_update": "2026-07-20", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06161532", "title": "Sacituzumab Govitecan With or Without Atezolizumab Immunotherapy in Rare Genitourinary Tumors (SMART) Such as High Grade Neuroendocrine Carcinomas, Adenocarcinoma, and Squamous Cell Bladder/Urinary Tract Cancer, Renal Medullary Carcinoma and Penile C...", "status": "RECRUITING", "last_update": "2026-08-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06341478", "title": "Investigator Grant (IG) 2022 27746", "status": "RECRUITING", "last_update": "2024-04-02", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06682728", "title": "Adjuvant Sacituzumab Govitecan and Nivolumab in Muscle-Invasive Urothelial Carcinoma at High-Risk Recurrence", "status": "RECRUITING", "last_update": "2026-04-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01631552", "title": "Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer", "status": "COMPLETED", "last_update": "2021-08-12", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03869190", "title": "Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatments and Combinations in Patients With Urothelial Carcinoma (MORPHEUS-UC)", "status": "TERMINATED", "last_update": "2026-08-03", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04579224", "title": "Comparing the New Anti-cancer Drug Eribulin With Chemotherapy Against the Usual Chemotherapy Alone in Metastatic Urothelial Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-04", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04794699", "title": "Study of IDE397 in Participants With Solid Tumors Harboring MTAP Deletion", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-04-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04863885", "title": "Combination of Ipi/Nivo Plus Sacituzumab Govitecan in Metastatic Cisplatin Ineligible Urothelial Carcinoma Patients", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-12-17", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05226117", "title": "Sacituzumab Govitecan, Preceding Radical Cystectomy, in Treating Patients With Muscle-invasive Bladder Cancer", "status": "COMPLETED", "last_update": "2026-03-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05327530", "title": "A Study of the Safety and Efficacy of Various Combinations of Avelumab as Therapy in Locally Advanced or Metastatic Urothelial Carcinoma (JAVELIN Bladder Medley)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05535218", "title": "Pembrolizumab-Sacituzumab Govitecan Combination to Treat High-risk, Localized Bladder Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-04-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05581589", "title": "Sacituzumab Govitecan Before Radical Cystectomy for the Treatment of Non-Urothelial Muscle Invasive Bladder Cancer", "status": "TERMINATED", "last_update": "2026-04-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06133517", "title": "PeRioperative Immunotherapy Combined With Sacituzumab Govitecan in Muscle Invasive blAdder Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-03-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06204614", "title": "Drug Screening Using IMD in Bladder Cancer", "status": "ENROLLING_BY_INVITATION", "last_update": "2026-05-18", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06528483", "title": "Bladder Preservation With Sacituzumab Govitecan + Zimberelimab for Muscle-Invasive Bladder Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2024-07-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "TASELISIB": { "n": 1, "n_observational": 0, "n_active": 1, "n_withdrawn": 0, "trials": [ { "nct": "NCT02465060", "title": "Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "TRASTUZUMAB": { "n": 20, "n_observational": 2, "n_active": 9, "n_withdrawn": 2, "trials": [ { "nct": "NCT05614739", "title": "FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3", "status": "RECRUITING", "last_update": "2026-08-20", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05786716", "title": "DETERMINE Trial Treatment Arm 04: Trastuzumab in Combination With Pertuzumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With HER2 Amplification or Activating Mutations", "status": "RECRUITING", "last_update": "2025-12-02", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06253871", "title": "A Phase 1/1b Study of IAM1363 in HER2 Cancers", "status": "RECRUITING", "last_update": "2026-09-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00004074", "title": "Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu", "status": "COMPLETED", "last_update": "2013-02-28", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00004856", "title": "Trastuzumab in Treating Patients With Previously Treated, Locally Advanced, or Metastatic Cancer of the Urothelium", "status": "TERMINATED", "last_update": "2013-05-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00005831", "title": "Trastuzumab and Combination Chemotherapy in Treating Patients With Locally Recurrent or Metastatic Urinary Tract Cancer", "status": "COMPLETED", "last_update": "2013-01-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00005842", "title": "Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic Cancer", "status": "COMPLETED", "last_update": "2013-02-11", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00238420", "title": "Paclitaxel and Radiation Therapy With or Without Trastuzumab in Treating Patients Who Have Undergone Surgery for Bladder Cancer", "status": "COMPLETED", "last_update": "2022-07-19", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01828736", "title": "Efficacy of Combination of Trastuzumab to Gemcitabine - Platinum Advanced or Metastatic Urothelial Carcinoma", "status": "COMPLETED", "last_update": "2017-02-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02091141", "title": "My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors", "status": "COMPLETED", "last_update": "2024-07-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02465060", "title": "Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02675829", "title": "Trial of Ado-Trastuzumab Emtansine for Patients With HER2 Amplified or Mutant Cancers", "status": "COMPLETED", "last_update": "2026-09-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02999672", "title": "A Study to Determine Best Tumor Response With Trastuzumab Emtansine in Human Epidermal Growth Factor Receptor 2 (HER2) Overexpressing Solid Tumors", "status": "COMPLETED", "last_update": "2019-08-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04464967", "title": "Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR Cancers", "status": "WITHDRAWN", "last_update": "2021-05-12", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04482309", "title": "A Phase 2 Study of T-DXd in Patients With Selected HER2 Expressing Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04602117", "title": "ISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer", "status": "WITHDRAWN", "last_update": "2023-11-18", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04644068", "title": "Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-19", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06630871", "title": "A Clinical Trial Evaluating the Efficacy and Safety of Disitamab Vedotin Plus Tislelizumab Combined with Re-TURBT in the Treatment of HER-2-high Expression(2+-3+) Non-muscle Invasive Bladder Cancer At High-risk and Very High-risk.", "status": "NOT_YET_RECRUITING", "last_update": "2024-10-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07624201", "title": "Trastuzumab Rezetecan and Adebrelimab as Neoadjuvant Therapy for HER2-Positive Muscle-Invasive Bladder Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2026-06-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07639983", "title": "Multi-Omics-Based Phase \u2161 Trial of Trastuzumab Rezetecan Plus Camrelizumab for Perioperative Therapy in HER2-Positive Muscle-Invasive Urothelial Carcinoma", "status": "NOT_YET_RECRUITING", "last_update": "2026-06-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "TRASTUZUMAB DERUXTECAN": { "n": 3, "n_observational": 2, "n_active": 3, "n_withdrawn": 0, "trials": [ { "nct": "NCT05614739", "title": "FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3", "status": "RECRUITING", "last_update": "2026-08-20", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04482309", "title": "A Phase 2 Study of T-DXd in Patients With Selected HER2 Expressing Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04644068", "title": "Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-19", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" } ] }, "TRASTUZUMAB DUOCARMAZINE": { "n": 1, "n_observational": 0, "n_active": 0, "n_withdrawn": 1, "trials": [ { "nct": "NCT04602117", "title": "ISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer", "status": "WITHDRAWN", "last_update": "2023-11-18", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ] }, "TRASTUZUMAB EMTANSINE": { "n": 3, "n_observational": 0, "n_active": 1, "n_withdrawn": 0, "trials": [ { "nct": "NCT02465060", "title": "Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02675829", "title": "Trial of Ado-Trastuzumab Emtansine for Patients With HER2 Amplified or Mutant Cancers", "status": "COMPLETED", "last_update": "2026-09-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02999672", "title": "A Study to Determine Best Tumor Response With Trastuzumab Emtansine in Human Epidermal Growth Factor Receptor 2 (HER2) Overexpressing Solid Tumors", "status": "COMPLETED", "last_update": "2019-08-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "VANDETANIB": { "n": 3, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT00880334", "title": "Randomized Study of Docetaxel +/- Vandetanib in Metastatic TCC", "status": "COMPLETED", "last_update": "2018-09-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01191892", "title": "Carboplatin and Gemcitabine Hydrochloride With or Without Vandetanib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Urinary Tract Cancer", "status": "COMPLETED", "last_update": "2019-05-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02788201", "title": "Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma", "status": "COMPLETED", "last_update": "2020-11-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "VOFATAMAB": { "n": 3, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT02401542", "title": "Dose Escalation, Expansion Study of Vofatamab (B-701) in Treatment of Locally Advanced or Metastatic Urothelial Cell Carcinoma", "status": "TERMINATED", "last_update": "2020-03-09", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03123055", "title": "A Study of B-701 in Combination With Pembrolizumab in Treatment of Locally Advanced or Metastatic Urothelial Cell Carcinoma", "status": "TERMINATED", "last_update": "2020-03-18", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05363605", "title": "A Study of [225Ac]-FPI-1966 in Participants With Advanced Solid Tumours", "status": "TERMINATED", "last_update": "2023-12-19", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" } ] }, "ZANIDATAMAB": { "n": 3, "n_observational": 0, "n_active": 2, "n_withdrawn": 0, "trials": [ { "nct": "NCT06253871", "title": "A Phase 1/1b Study of IAM1363 in HER2 Cancers", "status": "RECRUITING", "last_update": "2026-09-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07296705", "title": "Neoadjuvant Zanidatamab + Tislelizumab + Chemotherapy for Selective Bladder Preservation in HER2-Positive MIBC", "status": "RECRUITING", "last_update": "2025-12-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03929666", "title": "A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer", "status": "COMPLETED", "last_update": "2025-09-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] } } } }